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Abstract
Cerebral cavernous malformations (CCMs), or cavernomas, are abnormal vascular growths that arise in
the central nervous system and have no approved medical treatment. Considered a monogenic disease
caused by loss of function mutations in the CCM genes, the vast majority of CCMs arise in adults, often
presenting as a single fast-growing lesion that culminates in hemorrhage or seizure. Though
environmental differences explain the heterogeneity between individuals, why a single cavernoma
suddenly becomes aggressive is unknown. Our study reveals a synergistic interaction that underlies a
significant proportion of aggressive human CCMs and answers this long-standing question in the field.
Using mouse genetic models, we show that cavernoma growth requires two distinct inputs, one through
loss of the CCM protein complex as previously described, and another through gain of PI3K signaling,
which can be provided either by endogenous angiogenic signals in the neonatal mouse model or by
activating mutations in PIK3CA commonly found in cancer. We generated a novel adult mouse model that
confirms neither CCM loss nor PI3K gain alone are sufficient, but together, lead to rapid growth of a
cavernoma. We identify somatic mutations in PIK3CA in 71% of resected human cavernomas and via
single-nucleus DNA sequencing, reveal that PIK3CA mutations arise in the same cells as CCM gene
mutations. Considering that asymptomatic CCMs are not resected, this suggests that PIK3CA mutations
play a driving role in clinically symptomatic lesions. Our study establishes a “three-hit” mechanism
analogous to cancer in which aggressive vascular malformations arise through the loss of vascular
“suppressor genes” required to constrain vessel growth and gain of a vascular “oncogene” that stimulates
excess vessel growth. To our knowledge, this is the first description of a compound genetic mechanism
in vascular malformation pathogenesis. Consistent with these findings, the mTORC1 inhibitor Rapamycin
effectively blocks CCM formation in both neonatal and adult mouse models. These studies suggest that
clinically approved mTORC1 inhibitors are a promising therapeutic avenue for CCM disease, which at
present can only be treated with neurosurgical resection.
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ABSTRACT
INVESTIGATING THE ROLE OF PI3K SIGNALING IN
CEREBRAL CAVERNOUS MALFORMATION PATHOGENESIS
Aileen Ren
Mark L. Kahn, MD
Cerebral cavernous malformations (CCMs), or cavernomas, are abnormal vascular
growths that arise in the central nervous system and have no approved medical treatment.
Considered a monogenic disease caused by loss of function mutations in the CCM genes,
the vast majority of CCMs arise in adults, often presenting as a single fast-growing lesion
that culminates in hemorrhage or seizure. Though environmental differences explain the
heterogeneity between individuals, why a single cavernoma suddenly becomes aggressive
is unknown. Our study reveals a synergistic interaction that underlies a significant
proportion of aggressive human CCMs and answers this long-standing question in the field.
Using mouse genetic models, we show that cavernoma growth requires two distinct inputs,
one through loss of the CCM protein complex as previously described, and another through
gain of PI3K signaling, which can be provided either by endogenous angiogenic signals in
the neonatal mouse model or by activating mutations in PIK3CA commonly found in
cancer. We generated a novel adult mouse model that confirms neither CCM loss nor PI3K
gain alone are sufficient, but together, lead to rapid growth of a cavernoma. We identify
somatic mutations in PIK3CA in 71% of resected human cavernomas and via singlenucleus DNA sequencing, reveal that PIK3CA mutations arise in the same cells as CCM
gene mutations. Considering that asymptomatic CCMs are not resected, this suggests that
PIK3CA mutations play a driving role in clinically symptomatic lesions. Our study
iii

establishes a “three-hit” mechanism analogous to cancer in which aggressive vascular
malformations arise through the loss of vascular “suppressor genes” required to constrain
vessel growth and gain of a vascular “oncogene” that stimulates excess vessel growth. To
our knowledge, this is the first description of a compound genetic mechanism in vascular
malformation pathogenesis. Consistent with these findings, the mTORC1 inhibitor
Rapamycin effectively blocks CCM formation in both neonatal and adult mouse models.
These studies suggest that clinically approved mTORC1 inhibitors are a promising
therapeutic avenue for CCM disease, which at present can only be treated with
neurosurgical resection.
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CHAPTER 1: Introduction
Some of the text and figures in Chapter 1 have been published in and modified from an
invited review article in Circulation Research (2021).
This chapter introduces background information relevant to the experimental
studies that will be discussed in Chapter 2: PIK3CA and CCM Mutations Fuel Cavernomas
through a Cancer-like Mechanism. This section will introduce the clinical and scientific
background of cerebral cavernous malformations (CCMs), a human genetic
cerebrovascular disease, and review the scientific community’s efforts to understand its
pathogenesis. I will present molecular signaling pathways that are relevant to the disease
including a discussion of prior work from our laboratory. The last part will discuss the role
of PI3K signaling in vascular malformations particularly relevant to my thesis work.

1.1 What are Cerebral Cavernous Malformations?
Cerebral cavernous malformations (CCMs) also known as cavernous angiomas, or
cavernomas are a type of vascular lesion that form in the central nervous system. CCM
lesions are composed of caverns of dilated vessels arising from a single layer of
endothelium at the capillary venous junction. They are often described as being “mulberrylike” structures or “popcorn-like” due to the clusters of blood-filled caverns that are visible
on magnetic resonance imaging1. These malformations differ from other neurovascular
lesions such as brain arteriovenous malformations (AVMs) or arterial aneurysms. As a
result, they are slow flowing lesions and do not present with massive hemorrhage the way
these other fast flow lesions do. CCMs are not a major underlying cause of cerebrovascular
1

disease, but their investigation has been unusually fruitful and provided unexpected
molecular and genetic insight into vascular development and disease.
In this dissertation, I will use the abbreviation “CCM” to indicate the disease,
“KRIT1” to indicate the protein. For the genes, I will use “KRIT1” to indicate human gene,
and “Krit1” to indicate the mouse gene.
1.2 Epidemiology and clinical presentation of CCMs
Worldwide, the incidence of CCM disease is estimated to be about 0.1 – 0.5% of
the general population. This number is thought to be higher due to undiscovered disease,
identified only at the time of autopsy2. CCM disease for the most part remains silent, only
presenting with symptoms when the vascular lesion becomes problematic. As a result,
many are discovered incidentally on MRI scans due to other reasons, but these incidental
lesions often remain asymptomatic and do not require resection3. 20-50% of individuals
with diagnosed with CCM remain symptom free throughout their lifetime4,5. When lesions
do present with symptoms, the most frequent symptoms include seizures, focal neurologic
deficits, non-specific headaches, and cerebral hemorrhage6,7. Patients with CCM disease
can present with a broad range of symptoms, most often during the 2nd to 5th decades of
life8. In one of the largest cross-sectional studies of familial patients, the mean age of
clinical onset was thirty years with approximately fifty percent presenting with seizures
and thirty percent presenting with cerebral hemorrhage6,9. In familial patients greater than
fifty years of age, most were symptom-free, and several did not have any detectable lesions
upon MRI, demonstrating the incomplete penetrance of this disease. Despite the relative
2

rarity of this disease, it is a predominant cause of stroke in young people and often occurs
suddenly and without any inciting factors and therefore worth further investigation. Once
a symptomatic hemorrhage has occurred, the annual risk of a subsequent episode of
bleeding is increased 10-fold 4,5.
1.3 Clinical management of CCM disease
Despite major advancements in the scientific understanding of the disease
mechanism, standard of care has not changed and there is little we can offer patients who
have CCM disease. Standard of care for patients with cavernomas remains clinical
observation, symptomatic management such as with anti-seizure drugs, and ultimately,
neurosurgical resection of dangerous lesions, usually after hemorrhagic stroke8. As with
most surgical treatment, indication varies by the individual and is based on a variety of
factors including location and size of lesion or new hemorrhage10. Surgery is difficult,
expensive, and can be associated with significant morbidity and mortality. In addition,
there are lesions not surgically accessible or considered too risky to operate on, such as
those in the brain stem. Stereotactic radiosurgery has also been used by the field as an
alternative to surgery, but it is a controversial technique. In fact, a study examining
radiation sclerosis of CCM lesions resulted in more cavernomas11,12. In hindsight, this is
an unsurprising result. The observation that radiation treatment may induce CCM
formation supports a key role for somatic mutations in CCM pathogenesis. There is a
critical need for non-invasive medical therapies aimed towards preventing and alleviating
CCM lesions.
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Further complicating clinical management is the unpredictable disease course —
lesion number and symptomatic progression, such as hemorrhage or neurologic deficit, is
wildly variable, even within families13. Given the variable presentation of this disease, the
field has an interest in understanding the other pathways that contribute to CCM disease.
1.4 Genetic causes of CCM disease
There are two forms of cavernous angioma – familial and sporadic. Most CCMs
(~80%) arise spontaneously as individual “sporadic” lesions which are not heritable. A
smaller fraction of CCMs present as an inherited familial disease with an autosomal
dominant pattern of inheritance14,15. Unlike sporadic lesions which occur as isolated
lesions, individuals with familial disease can present with multiple lesions7. Both familial
and sporadic forms of CCM disease have been shown to be caused by loss-of-function
(LOF) mutations in the genes KRIT1 (CCM1), CCM2, or PDCD10 (CCM3) 16-18. Mutations
in these genes primarily consist of nonsense, frameshift, and canonical splice-site
mutations. Patients with familial disease are identified to be germline heterozygous for one
mutation. Despite being inherited autosomal dominant fashion, the gene itself is considered
recessive. No patients have identified to be homozygous null for these genes, likely
considering that these mutations would be incompatible with life.
The prevailing hypothesis in CCM disease caused by CCM mutations is that a
second-hit LOF mutation in a brain endothelial cell, regardless of familial or sporadic
origin, is causative for lesion genesis

19,20

. Patients with the familial form of the disease

gain a second hit later in life, requiring one additional somatic mutation on top of their
4

inherited mutation. The formation of sporadic lesions is seeded by the acquisition of two
somatic mutations. This likely explains why sporadic CCM patients typically develop
solitary lesions – it would be exceedingly rare for an individual to acquire two mutations
on both copies of the same gene within a single cell. Recent studies also have shown that
a single, activating MAP3K3 mutation is also sufficient to cause CCM disease, which is
consistent with the role of the CCM complex as described in more depth below. There is
no distinguishable morphology between sporadic and familial disease and those caused by
CCM mutations or MAP3K3 mutations.
1.5 The CCM protein complex
Identification of the mutant genes responsible for CCM disease in familial CCM
disease patients revealed three non-homologous proteins with protein binding motifs, but
no enzymatic or transcriptional activity. KRIT1, CCM2, and PDCD10 are highly
conserved between humans and mice at the amino acid level. Targeted, null alleles of Krit1,
Ccm2, and Pdcd10 were generated in mice and homozygous null animals exhibit fully
penetrant embryonic lethality. How three distinct proteins caused one clinical syndrome
became clear when biochemical studies demonstrated that KRIT1, CCM2 and PDCD10
form a molecular complex21-23. Together these three genes code for non-homologous
proteins that form a heterotrimeric CCM adaptor complex24.
In vivo studies using genetic model organisms have revealed that the heterotrimeric
“CCM complex” is required for cardiovascular development25-28. These phenotypes were
reproduced following endothelial-specific gene deletion29-32, suggesting that CCM
5

function is required specifically in endothelial cells, but a molecular mechanism of action
and a facile animal model with which to investigate disease pathogenesis remained elusive.
This barrier was broken with the seminal demonstration that deletion of CCM genes in
neonatal mice is sufficient to confer robust CCM formation29. Using this neonatal model,
numerous groups have subsequently demonstrated that endothelial loss of CCM complex
function is sufficient to confer lesion formation, confirming that the endothelial cell is the
site of action for the CCM complex.
How does an adaptor protein complex regulate endothelial cell function? A critical
clue to the molecular basis of CCM function arose prior to the identification of the diseasecausing genes from studies of the MAP3K3 kinase, MEKK3. A yeast two-hybrid screen
performed using MEKK3 as bait identified strong interaction with an uncharacterized
protein, OSM, later identified as CCM2. This interaction was confirmed biochemically and
characterized structurally33,34, establishing that the CCM complex binds MEKK3 through
the CCM2 protein that also binds KRIT1 and PDCD10.
Genetic studies in the developing heart defined the functional significance of this
interaction, demonstrating that CCM function is required to negatively regulate MEKK3
function in vivo32. Importantly, this essential functional role was confirmed in the neonatal
mouse brain, where loss of MEKK3 or either of its established downstream transcriptional
effectors, KLF2 or KLF4, was found to be sufficient to prevent CCM formation following
endothelial cell loss of CCM function35. These studies have established the MEKK3KLF2/4 signaling pathway as a central signaling axis in CCM disease pathogenesis.

6

1.6 Molecular pathways of CCM-MEKK3-KLF2/4 signaling
The CCM complex is the center of a wide variety of signaling, integrating a large
number of upstream signals, and then modifying downstream pathways via MEKK3. In
vitro and in vivo studies in mice have defined two major inputs to the MEKK3-KLF2/4
signaling pathway in endothelial cells: hemodynamic shear forces and inflammatory
signals. Both have been implicated in CCM disease pathogenesis, as discussed below.
Flow and Shear forces: The best characterized input to endothelial MEKK3-KLF2/4
signaling is hemodynamic shear force; thus, it logical to consider that hemodynamic forces
play a significant role in CCM disease. Studies in the developing zebrafish and mouse
embryo have demonstrated that MEKK3-KLF2/4 signaling is regulated by fluid shear
forces during cardiovascular development36-38. The CCM complex has been shown to
regulate the MEKK3-KLF2/4 pathway in this context, and its manipulation alters
cardiovascular developmental processes linked to fluid forces in the zebrafish embryo32,3943

. CCM lesions in the brain first arise in post-capillary venules, a site of extremely low

fluid shear. However, the beta blocker propranolol, an agent that reduces cardiac output
and hemodynamic shear forces, ameliorates both zebrafish developmental phenotypes and
postnatal CCM lesions conferred by CCM loss of function42. Future studies that focus on
hemodynamic shear forces specifically in the venules and veins of the postnatal brain will
better define the role of this upstream input in CCM pathogenesis.
Inflammation: Studies of MEKK3 signaling in cultured fibroblasts have demonstrated that
it is required for innate immune inflammatory signaling in response to lipopolysaccharide
7

(LPS) and interleukin 1b (IL1b)44. A first clue linking CCM disease to inflammatory
signals in brain endothelial cells came from human genetic studies that associated
polymorphisms in the genes encoding the LPS receptor TLR4 and its co-receptor CD14
with more severe familial CCM disease 45. Susceptibility to CCM lesion formation in mice
tracked with the GNB content of the gut microbiome, and treatment of susceptible animals
with antibiotics or housing in germ-free conditions prevented CCM formation46, indicating
that LPS from GNB that reside in the gut microbiome is an essential driver of CCM
formation in the brain. Importantly, these studies in mice are supported by analysis of the
gut microbiome in humans with and without symptomatic CCM disease. These studies
established a particularly straightforward gut-brain disease axis in which GNB in the gut
microbiome provide a ligand, LPS, required to activate TLR4 receptors and downstream
MEKK3-KLF2/4 signaling in brain endothelial cells.
Downstream pathways still remain nebulous and need to be investigated more
thoroughly, though we believe the primary pathway to be through MEKK3 and KLF2/4.
KLF2 and KLF4 are transcription factors and therefore impact a host of genes that have
yet to be thoroughly tested in CCM pathogenesis. One such target we have identified in lab
include the ADAMTS family of metalloproteases responsible for cleaving the extracellular
matrix proteoglycan, versican47. We have shown that loss of ADAMTS5 rescues some
aspects of the CCM phenotype in the CCM neonatal mouse model and also that ADAMTS5
is sufficient to reproduce some characteristic phenotypes of CCM disease. Other targets
identified through transcriptomic analysis of inactivation of Krit1 or Pdcd10 found
increased levels of Thbd mRNA, which encodes the natural anticoagulant receptor,
8

thrombomodulin, which can impact bleeding phenotypes and serves as an important
translational pathway to investigate48,49. These major pathways and others not described in
this brief introduction are summarized in Figure 1 below.
1.7 PI3K signaling in angiogenesis
Phosphatidylinositol 3-kinase (PI3K) is a highly conserved enzyme across all
multicellular organisms, established to play a causal role in growth, cellular proliferation,
and metabolic regulation in response to external signals. PI3K functions as a kinase to
modulate lipid second messenger PIP2 by converting it to PIP3. This is counteracted by
the activity of phosphatase and tensin homolog (PTEN) which is a phosphatase responsible
for converting PIP3 back into PIP2. The delicate balance of these two opposing enzymes
is responsible for most of the control of the downstream signal transduction cascade. The
major pathway by which PI3K signals through is via key effectors, AKT and mammalian
target of rapamycin (mTOR) along with a host of other regulatory proteins.
In the field of vascular biology, PI3K is known as a master regulator of
angiogenesis. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that
mediates its effects primarily through the PI3K pathway. When VEGF binds to its receptor
on endothelial cells, the PI3K pathway is activated. The endothelial cell is very sensitive
to PI3K signaling modulations and an interesting observation from in vivo mouse studies
is that both too much and too little activation of p110α leads to embryonic lethality due to
incomplete development of blood vessels50. The catalytic domain of PI3K, p110α is
necessary for angiogenesis and controls endothelial cell migration, regulates barrier
function, and also junction morphology. It is the sole isoform required for blood and
9

lymphatic vascular development50-52. As a result, it is unsurprising that mutations in this
pathway can greatly disrupt vascular physiology.
1.8 PIK3CA mutations in vascular malformations
PIK3CA is the gene that encodes the p110α isoform of PI3K that is the catalytically
active site and is most commonly mutated PI3K gene in human cancers. The most common
activating mutations occur in the helical (E542K, E542K) and kinase (H1047R, H1047L)
domains of PIK3CA53. These two types of mutations lead to a constitutive binding of p110a
to the plasma membrane by gain-of-function mechanisms which trigger an overactivation
of the PI3K signaling pathway54. These oncogenic PIK3CA mutations are also the same
ones known to cause venous and lymphatic malformations55-60. It was discovered that most
lymphatic malformations were caused by mutations in the PIK3CA gene59 and about 2530% of venous malformations are also caused by these oncogenic PIK3CA mutations 60-62.
These vascular malformations are largely considered monogenic disorders, with common
mutations occurring mutually exclusive of one another63.
However, the exact mechanism by which PIK3CA mutations causes these vascular
malformations is still unknown. There have been in vitro studies have attempted to answer
these questions. For example, PIK3CA-mutant lymphatic endothelial cells show enhanced
proliferation and sprouting capacity. Recently, a study published the first PIK3CA-driven
mouse

model

of

lymphatic

malformations

that

resembles

human

lymphatic

malformations56. People have shown the ability of PI3K inhibitors or downstream effector
inhibitors to rescue, both molecularly and functionally, the phenotypes of these mutations
10

and resulting malformations64. Research done in the cancer field may be applied to the
understanding of lymphatic malformations and venous malformations. Likewise,
repurposing PI3K pathway inhibitors that are currently in cancer clinical trials can be used
as a novel strategy for the treatment of these diseases.
The hypothesis I propose for my thesis work is that PI3K signaling plays a role in
the pathogenesis of CCM disease. PI3K signaling has been proposed to be associated with
CCMs previously, though the connection has never been entirely apparent65. CCM lesions
have been observed to be VEGF high66,67, supporting the idea that VEGF signaling is
altered in this disease. Addition of the angiogenic growth factor VEGF-A68 or loss of the
anti-angiogenic factor TSP148 is also known to augment CCM formation. Hypoxia leads to
HIF-1α stabilization and is a major stimulus for increased VEGF production. The
involvement of PTEN promoter methylation in CCM was also reported69 but the
mechanism and role was unclear. Ultimately, these disparate papers converge on a single
unified hypothesis that angiogenesis plays a role in CCM disease.
1.9 Figures

11

Figure 1-1

Figure 1-1. Molecular signaling pathways involved in cerebral cavernous
malformation (CCM) lesion formation.
Shown is a partial summary of the various upstream inputs and downstream effectors
implicated in CCM signaling. The heterotrimeric CCM complex, consisting of CCM1
(KRIT1 [Krev interaction trapped protein 1]), CCM2, and CCM3 (PDCD10
[programmed cell death protein 10]), is an inhibitor of MAP3K3 kinase, MEKK3
(mitogen-activated protein kinase kinase kinase 3). Inflammatory signals via TLR4 (Tolllike receptor 4) serve as the upstream input into MEKK3 signaling, as may shear forces
associated with blood flow (not shown). Loss of CCM and subsequent activation of
MEKK3 leads to upregulation of transcription factors KLF2 (Krüppel-like factor 2) and
KLF4. Downstream KLF2/4 transcriptional targets include both cell-autonomous
pathways through PI3K signaling and RHO/ROCK signaling, as well as cell
nonautonomous effects via metalloprotease ADAMTS5 (ADAM metallopeptidase with
thrombospondin type 1 motif 5) and extracellular matrix cleavage. VEGF is shown as a
possible distinct input for PI3K-mTOR signaling while HEG1 (protein HEG homolog 1)
has been associated with regulation of endothelial cell junctions. Of note, numerous other
pathways have been found to be affected by loss of CCM function. This diagram focuses
on those that are presently best understood and those that have been investigated using
mouse and human genetic studies and are presently targeted therapeutically.
12

CHAPTER 2: PIK3CA and CCM mutations fuel cavernomas through a
cancer-like mechanism
The following text and figures have been published in and modified from Ren AA,
Snellings DA, et al. Nature, 2021.

2.1 Abstract
Vascular malformations are considered monogenic disorders that result in
dysregulated vessel growth. Cerebral cavernous malformations (CCMs) are common
vascular malformations that arise due to inactivation of the endothelial CCM protein
complex required to dampen MEKK3 activity. Environmental factors explain differences
in CCM natural history between individuals, but why single CCMs often exhibit sudden
and rapid growth that culminates in stroke or seizure is not known. Here we demonstrate
that CCM growth in both humans and mice requires gain of PI3K-mTOR signaling in
addition to loss of CCM function. We identify somatic gain-of-function mutations in
PIK3CA, the gene encoding the catalytic subunit of PI3K, in 71% of resected human CCM
lesions. Single-nucleus DNA sequencing of human lesions reveals that PIK3CA mutations
arise in the same cells as CCM somatic mutations. Using mouse genetic models, we show
that CCM growth requires both CCM loss of function and PI3K gain of function in
endothelial cells, provided in the neonate by endogenous angiogenic signals or in the adult
by expression of PIK3CA H1047R. Mechanistically, both loss of CCM function and
increased expression of the transcription factor KLF4, a causal MEKK3 effector in CCM
disease, augment PI3K-mTOR signaling in endothelial cells. Consistent with these
findings, the mTORC1 inhibitor Rapamycin effectively blocks CCM formation in both
13

neonatal and adult mouse models. These studies establish a multiple hit mechanism
analogous to cancer in which aggressive vascular malformations arise through the loss of
vascular “suppressor genes” required to constrain vessel growth and gain of a vascular
“oncogene” that stimulates excess vessel growth. They further suggest that aggressive
CCMs may be medically treated using clinically approved mTORC1 inhibitors.
2.2 Introduction
Vascular malformations such as cerebral cavernous malformations (CCMs) that
arise in the central nervous system are an important cause of stroke and disability in
younger individuals 70,71. Most CCMs arise sporadically as single lesions, but a minority
present as part of a familial, autosomal dominant form of the disease that is associated with
multiple lesions8. Classic genetic studies have associated familial CCM disease with
heterozygous germline loss of function mutations in three genes, KRIT1, CCM2, and
PDCD10, that encode the components of a heterotrimeric protein complex (the “CCM
complex”)24,72. Subsequent studies have demonstrated that CCM lesions harbor an
additional somatic mutation in the same gene as the germline mutation, implicating
biallelic loss of function of the affected CCM gene as the cause of the disease73

19

.

Consistent with this monogenic loss of function mechanism, sporadic CCMs harbor
biallelic somatic mutations in one of the CCM genes, resulting in homozygous loss of
function74. Mouse models confirm that deletion of any of the CCM genes in brain
endothelial cells of neonatal mice confers CCM lesions, proving a causal role for loss of
CCM complex function in this disease. These studies have generated the current genetic
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model of CCM pathogenesis in which biallelic loss of function mutations in a single CCM
gene is sufficient for CCM lesion development.
Recent genetic, biochemical, and cellular studies have revealed that loss of CCM
function results in vascular lesion formation due to increased MEKK3-KLF2/4 signaling
in brain endothelial cells35,41,75,76, and that CCM disease may be strongly influenced by the
gut microbiome due to its role in stimulating brain endothelial TLR4 receptors that signal
through MEKK3

46,74,77

. A genome wide association study (GWAS) identified

polymorphisms in the genes encoding TLR4 and its co-receptor CD14 that up-regulate their
expression and accelerate CCM disease course

45,46

, but other genetic drivers of lesion

genesis or growth have not been identified or suspected.
Serial imaging studies of human CCMs has revealed that most are slow-growing
and clinically silent 4,5,78. In contrast, those that cause stroke and seizure are typically fastgrowing and associated with repeated lesional hemorrhage

10,79

. Such aggressive,

symptomatic lesions are surgically resected if possible to prevent or treat associated
neurologic complications, but surgery is associated with high morbidity and cost and is
impractical for patients with multiple lesions or lesions in less surgically-accessible
locations such as the brain stem. Why a subset of CCM lesions exhibits rapid growth
associated with clinical symptoms is unknown.
Recent mouse and human studies suggest that a gut microbiome containing more
invasive gram-negative bacteria or an impairment of the gut barrier that blocks
translocation of bacterial products such as lipopolysaccharide may modulate CCM growth
15

through effects on TLR4-MEKK3-KLF2/4 signaling in brain endothelial cells46 ,77,80,81.
Plasma biomarkers of angiogenesis have also been correlated with lesional clinical activity
82,83

. However, individuals with familial CCM disease who harbor numerous silent lesions

identified by MRI imaging also often manifest symptomatic hemorrhage and aggressive
growth of only a single lesion 84. Thus the current understanding of the environmental and
genetic factors that contribute to CCM growth fails to explain important aspects of the
disease natural history, especially the emergence of rapidly growing symptomatic lesions
which account for the majority of adverse clinical outcomes.
Recent studies of sporadic vascular malformations have identified acquired gain of
function mutations in a number of central signaling pathways, including the
RAS/MAPK/ERK pathway in congenital hemangiomas and capillary malformations and
the PI3K/AKT/mTOR pathway in venous and lymphatic malformations 55-60 (and reviewed
in 85). Many of these gain of function mutations, e.g. those in PIK3CA, the catalytic subunit
of PI3K, are identical to those that have been identified in cancer cells60-62,86,87. However,
unlike cancer, in which mutations in multiple driver genes such as tumor suppressor genes
and oncogenes combine to promote growth88,89, the pathogenesis of vascular
malformations has been considered monogenic. The studies described below reveal that
symptomatic CCM disease arises through a cancer-like paradigm in which the
accumulation of multiple somatic mutations in the same cell results in both the loss of a
vascular malformation suppressor gene (i.e. the CCM gene) and the gain of vascular
malformation growth gene (i.e. PIK3CA).
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2.3 CCM gene deletion in mature mice form testicular cavernomas
The established animal model for CCM investigation is the mouse neonate because
CCMs grow rapidly in the angiogenic environment of the postnatal retina and hindbrain
following genetic endothelial cell deletion of Krit1, Ccm2 or Pdcd10, the 3 genes that
encode components of the CCM complex35,90-92. Importantly, although the vast majority of
human CCM lesions arise and grow in adults, we and others have found that CCMs do not
form in the brain or CNS following pan-endothelial or brain endothelial gene deletion in
adult mice35,90,92. Consistent with these prior observations, tamoxifen-induced endothelial
genetic deletion of a floxed Krit1 allele (Krit1fl/fl) with a Cdh5-CreERT2 transgene on P1
resulted in the formation of numerous CCM lesions that were detected both visually and
histologically in the white matter venous vessels of the hindbrain at P10 (Extended Data
Fig. 1a, b). In contrast, tamoxifen administration to Cdh5-CreERT2;Krit1fl/fl animals from
the same colony (and therefore with an equivalent gut microbiome) at age 2 months failed
to induce CCM lesions in the brain (Extended Data Fig. 1c, d). These findings suggested
either that mature mice are protected from CCM formation following endothelial loss of
CCM function through a mechanism not present in humans, or that factor(s) other than
endothelial loss of CCM function are required for lesion formation after the neonatal
period.
To more fully assess the long-term effects of endothelial CCM loss of function in
mature mice we administered tamoxifen to 2-month-old Cdh5-CreERT2;Krit1fl/fl animals
(hereafter termed “Krit1iECKO” for inducible Endothelial Cell Knock Out) and examined
the vascular beds of all organs histologically at 6 months. The vasculature of all organs
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appeared unchanged with the exception of the testis. The Krit1iECKO testis appeared bloody
and swollen compared with those of Krit1fl/fl control littermates that also received
tamoxifen (Extended Data Fig. 1e). Histologic examination of the testis revealed the
presence of dilated, blood-filled caverns similar to those observed in the mouse neonatal
hindbrain or resected human CCM lesions (Extended Data Fig. 1e vs. 1b and

35,93

). A

molecular hallmark and causal mechanism of CCM formation in both mouse neonatal
lesions and human CCM lesions is elevated expression of the KLF4 transcription factor in
endothelial cell nuclei 35,48,76,94. Immunostaining revealed KLF4 expression in the majority
of endothelial nuclei in the testis of Krit1iECKO animals at 6 months, but not in control
littermates (Extended Data Fig. 1f, g). We also stained for DPEAAE, a versican neoepitope specifically generated by ADAMTS proteolysis, which we recently identified as a
causal event for CCM formation in the neonatal mouse model

35,47

. Consistent with the

KLF4 expression data, cleaved versican was present around the testicular cavernomas in
adult Krit1iECKO animals (Extended Data Fig. 1h). Despite a lack of CCM lesion formation
in the brain, immunostaining revealed elevated KLF4 levels in the brain endothelial cells
of adult Krit1iECKO animals (Extended Data Fig. 1f), indicating that the failure to form
CCMs in the adult brain vasculature does not merely reflect a failure to increase MEKK3KLF2/4 signaling following CCM gene deletion at that site. Thus despite similar increases
in downstream MEKK3-KLF3/4 signaling, endothelial loss of KRIT1 function in mature
mice is sufficient to confer cavernous vascular malformations in the testis, but not in the
brain.
2.4 PIK3CA gain of function synergizes with CCM loss of function in mice
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Why might cavernomas form in the testis but not the brain following CCM loss of
function in the endothelial cells of mature mice? Brain vascular growth is closely tied to
that of the underlying neural tissue, and both the retina and hindbrain, sites where CCMs
form selectively after CCM gene deletion at P1, grow extensively after birth in the mouse
(e.g. compared with the forebrain where lesion formation is observed with lower
frequency) 95-97. In the healthy adult rat, the endothelial cells of the testis exhibit the highest
rate of basal proliferation of those in all organs tested, incorporating BrdU in association
with DNA synthesis at a rate 5-10X that of brain endothelial cells

98

. We therefore

hypothesized that lesion formation following CCM loss of function might require signals
that are present in endothelial cells at sites of active angiogenesis, such as those associated
with endothelial cell proliferation. A central driver of angiogenesis is VEGF receptor
signaling that stimulates endothelial cell proliferation by activating the ERK1/2 and AKT
downstream signaling pathways

99,100

. AKT stimulates endothelial cell proliferation as a

central effector of the PI3K pathway, and gain of function mutations in the catalytic subunit
of PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
(PIK3CA), are known drivers of cell proliferation in cancer and have recently been shown
to confer venous and lymphatic malformations when they arise in endothelial cells
62,87

56,59-

. We therefore next tested whether genetic gain of PIK3CA function might augment

CCM formation in vivo. To this end, we used the Slco1c1(BAC)-CreERT2 transgene to
drive expression of a ROSA26 knock-in allele encoding PIK3CA H1047R (R26-LSLPik3caH1047R), the most common gain of function PIK3CA mutation observed in both
cancer and venous/lymphatic malformations101. The Slco1c1(BAC)-CreERT2 transgene
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was chosen to restrict PIK3CA H1047R expression to brain endothelial cells46,102, thereby
avoiding phenotypes in non-CNS vascular beds.
To test for interaction with loss of CCM function in the most stringent manner
possible, we bred the Cre-activated PIK3CA H1047R allele, R26-LSL-Pik3caH1047R, into
a Krit1fl/fl colony that fails to develop CCM lesions in the neonatal brain following loss of
KRIT1 alone due to the presence of a “resistant” gut microbiome that reduces basal
MEKK3-KLF2/4 signaling in brain endothelial cells (described in 46). Following tamoxifen
administration at P1, we examined Slco1c1(BAC)-CreERT2;Kritfl/fl (hereafter termed
Krit1iBECKO for inducible Brain Endothelial Cell Knock Out), Slco1c1(BAC)CreERT2;R26-LSL-Pik3caH1047R (hereafter termed Pik3caiBECGOF for inducible Brain
Endothelial Cell Gain Of Function), and Slco1c1(BAC)-CreERT2;Krit1fl/fl;R26-LSLPik3caH1047R (Krit1

iBECKO

;Pik3caiBECGOF) littermates at P7, a timepoint at which small,

nascent CCM lesions are detected in Krit1iBECKO animals that harbor a “susceptible” or
permissive microbiome 46 (Fig. 1a). As predicted by prior studies, Krit1iBECKO animals with
the resistant microbiome failed to develop CCM lesions (Fig. 1b, c). Consistent with prior
studies associating endothelial PIK3CA gain of function with venous malformation,
Pik3caiBECGOF animals developed small vascular lesions in the brain (Fig. 1b, c).
Significantly, visual and microCT analysis revealed a synergistic effect of CCM loss of
function and PIK3CA gain of function on lesion formation in Krit1iBECKO;Pik3caiBECGOF
double mutants (Fig. 1b, c). Hematoxylin-eosin staining of hindbrain sections from P6
Pik3caiBECGOF animals revealed dilated, blood-filled post-capillary venules and veins in the
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white matter, where venous vessels are located and where CCM lesions also first arise in
animals with a susceptible gut microbiome (Extended Data Fig. 2 and 35).
To exclude that the observed synergy might reflect an off-target effect of PIK3CA
H1047R due to forced expression from the ROSA26 locus, we next tested whether loss of
endogenous negative regulator of PI3K signaling might similarly augment CCM lesion
formation. Therefore, we genetically inactivated the lipid phosphatase PTEN, a wellcharacterized inhibitor of PI3K signaling that removes phosphates from PIP3. Endothelial
loss of one or two Pten alleles augmented CCM formation in a significant and dosedependent manner in neonatal animals (Extended Data Fig. 3). These findings reveal that
gain of PIK3CA function alone is sufficient to generate venous vascular lesions similar to
nascent CCMs, and that gain of PI3K signaling synergizes with loss of CCM function to
drive aggressive CCM lesion growth.
2.5 Combined PIK3CA gain of function and CCM loss of function is required for
CCM formation in the adult brain
The findings that cavernomas form in the adult testis, a site of higher endothelial
cell proliferation than the adult brain, and that gain of PI3K signaling, a pathway that
supports cell proliferation, synergizes with CCM loss of function during cavernoma
formation in the neonate suggested that in addition to loss of CCM gene function CCM
formation might require a threshold level of endothelial PI3K activity that is present in the
neonatal hindbrain and retina but not in the adult brain. To test this hypothesis, we first
designed a genetic approach to simultaneously induce PIK3CA gain of function and CCM
loss of function in the brain endothelial cells of adult mice using the Slco1c1(BAC)21

CreERT2 transgene. However, as litters containing Slco1c1(BAC)-CreERT2;Krit1fl/fl,
Slco1c1(BAC)-CreERT2;Krit1fl/+;R26-LSL-Pik3caH1047R,

and

Slco1c1(BAC)-

CreERT2;Krit1fl/fl;R26-LSL-Pik3caH1047R animals were aged, spontaneous neurologic
symptoms and lethality were observed in Slco1c1(BAC)-CreERT2;Krit1fl/fl;R26-LSLPik3caH1047R animals beginning 2-3 weeks after birth, with complete mortality of these
animals by age 3 months, in the absence of tamoxifen administration (Extended Data Fig.
4a,

b).

In

Slco1c1(BAC)-CreERT2;Krit1fl/fl

contrast,

and

Slco1c1(BAC)-

CreERT2;Krit1fl/+;R26-LSL-Pik3caH1047R littermates remained healthy and exhibited
normal survival (Extended Data Fig. 4b). Visual analysis of brains from P28 animals
revealed large single lesions specifically in Slco1c1(BAC)-CreERT2;Krit1fl/fl;R26-LSLPik3caH1047R animals, a finding that was confirmed by microCT analysis (Extended Data
Fig. 3c, d). Animals exhibiting neurologic symptoms at various timepoints between P19P36 all possessed focal brain lesions (Extended Data Fig. 4e). These findings suggested
that leak of the Slco1c1(BAC)-CreERT2 transgene, causing Cre-mediated recombination
in the absence of tamoxifen administration, is sufficient for lesion formation if it results in
both PIK3CA gain of function and CCM loss of function, but neither alone. To identify the
cellular site(s) of leaky (i.e. tamoxifen-independent) Cre-mediated recombination by the
Slco1c1(BAC)-CreERT2

transgene

we

examined

Cre

reporter

expression

in

Slco1c1(BAC)-CreERT2;R26-LSL-nTnG brains at P28 in the absence of tamoxifen. Leaky
Cre activity was 99% restricted to the vascular endothelial cell population (Extended Data
Fig. 4f, g). These studies confirm a remarkable synergy between CCM loss of function and
PIK3CA gain of function, and indicate that this synergy is mediated by interaction within
or between endothelial cells.
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To more rigorously address this question we next created cranial windows with
which to directly inject viral AAV vector encoding Cre recombinase into the brains of
Krit1fl/fl, Krit1fl/+;R26-LSL-Pik3caH1047R, and Krit1fl/fl;R26-LSL-Pik3caH1047R littermates at
age 2 months (Fig. 1d-g and Extended Data Fig. 5a-c). With this approach, the cranial
window enables both viral vector injection and serial visualization of the injection site over
time (Fig. 1e, f and Extended Data Fig. 5c). Genetic lineage tracing studies revealed that
direct injection of AAV-Cre into the brain resulted in Cre expression in both endothelial
and neuronal cells (Extended Data Fig. 6).

AAV-Cre injection into Krit1fl/fl or

Krit1fl/+;R26-LSL-Pik3caH1047R animals failed to confer lesion formation at 21 days. In
contrast, injection of Cre-encoding AAV into Krit1fl/fl;R26-LSL-Pik3caH1047R animals
resulted in the formation of large cavernomas at the site of injection (Fig. 1f-h and Extended
Data Fig. 5b). The vascular lesions induced by Cre injection into Krit1fl/fl;R26-LSLPik3caH1047R animals were first detected visually 7-10 days after injection (Fig. 1e and
Extended Data Fig 5c). By 21 days after injection, lesions exhibited the classic “mulberrylike” appearance characteristic of human CCMs, marked by a cluster of dark purple
vascular caverns

1

(Fig. 1e-f), and also demonstrated high levels of peri-lesional iron

deposition characteristic of human CCMs (Extended Data Fig. 5d). These studies
demonstrate that neither CCM loss of function nor PIK3CA gain of function alone is
sufficient for lesion formation in the mature brain, but that the combination of the two
results in the rapid formation of CCM lesions that are remarkably similar to those that arise
in human patients.
2.6 PIK3CA and CCM mutations in resected human CCMs
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To determine whether human CCM lesions harbor gain of function mutations in
PIK3CA or other genes that have been associated with increased cell growth and
proliferation, 79 surgically resected CCM lesions (a single lesion per individual) were
sequenced with a targeted panel of 66 genes that included the three causal CCM genes,
genes involved in PI3K signaling and associated pathways, other oncogenic pathway
genes, and other genes found to be mutated in vascular malformations (full gene list in
methods). The collected CCM lesions were classified as “familial”, “sporadic” or
“unknown” based on genetic and clinical evaluations (described in the methods). To ensure
that any sequence variants identified in the CCM lesions were specific to CCM disease, 68
distinct surgically resected human brain arteriovenous malformations (bAVMs) were
collected and sequenced. Since bAVMs and CCMs share a similar biological organization
but arise due to distinct pathogenic mechanisms, bAVMs provide a control with which to
identify mutations in CCM lesions that are specific to CCM pathogenesis.
Variants called from the sequencing data were filtered to select for those with at
least 5 supporting alternate reads, a variant allele frequency greater than 0.5%, predicted
functional consequence, and several other filtering criteria. Remarkably, sequencing
revealed that 56/79 (71%, P=1.23E-12) resected human CCM lesions harbor a somatic
mutation in PIK3CA (Fig. 2a, b and Supp. Table 1). In contrast, none of the 68 bAVM
samples harbored a somatic mutation in PIK3CA. All of the PIK3CA mutations occurred
at known hotspots in the catalogue of somatic mutations in cancer (COSMIC) (Fig. 2c).
Significantly, analysis of 62 other genes with listings in the COSMIC database failed to
identify mutations in any genes other than PIK3CA and the CCM genes. No mutations
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were found in other investigated components of the PI3K pathway, including PTEN and
AKT1/2/3, revealing striking specificity for PIK3CA mutations in human CCM. The three
most common PIK3CA mutations identified in CCM lesions (E542K, E545K, and
H1047R) were validated with droplet digital PCR and SNaPshot (single nucleotide
extension) assays. Mutations in PIK3CA were detected in 14/21 known familial lesions
(9/15 KRIT1, 4/5 CCM2, 1/1 PDCD10), and 12/15 known sporadic lesions (Fig. 4b). Each
CCM lesion harbored no more than one somatic mutation in PIK3CA, and all of the
PIK3CA mutations identified in CCM lesions have previously been determined to activate
PI3K signaling 103.
Previous studies have demonstrated that human CCM lesions harbor somatic
mutations in one of the three causal CCM genes. In this cohort, somatic mutations in CCM
genes were identified in 24/79 (30%) of CCM lesions. The relatively low discovery rate of
somatic CCM mutations may reflect types of mutations that are not detectable with shortread sequencing, such as large indels or chromosomal rearrangements that would be
detectable as loss of heterozygosity (LOH). However, the low somatic mutation allele
frequency observed in these and other vascular malformations precludes detection of LOH
by standard methods. Notably, in the CCM lesions in which we positively identified a
somatic loss of function CCM mutation, 21/24 (88%) also harbored a somatic gain of
function PIK3CA mutation. This apparent enrichment in the co-detection of CCM and
PIK3CA somatic mutations is consistent with sub-optimal sample quality that reduced
sensitivity and/or low variant allele frequency in many lesions. Thus, the true frequency of
PIK3CA mutations in CCM lesions is likely to be higher than the 71% reported above. The
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identification of multiple mutations in CCM genes is consistent with the previously
described two-hit model of CCM pathogenesis with the addition of a third hit in PIK3CA.
In 9 samples of familial CCM (‡ on Fig. 2a), we detected distinct loss of function germline
and somatic mutations in the same CCM gene in addition to a gain of function mutation in
PIK3CA for a total of 3 genetic hits. In 6 samples of presumed sporadic CCM (! on Fig.
2a), we detected two distinct loss of function somatic mutations in the same CCM gene in
addition to a gain of function mutation in PIK3CA for a total of 3 genetic hits (see Supp.
Table 1 for full genotyping dataset). These data indicate that no fewer than three
independent somatic mutation events contributed to the pathogenesis of those lesions. A
comparison of variant allele frequency between CCM and PIK3CA somatic mutations in
lesions where both mutations were found revealed no significant correlation (P > 0.15).
This balanced mutation frequency is consistent with a pathogenic mechanism in which both
CCM and PIK3CA somatic mutations arise in a single cell during lesion formation, or one
in which CCM mutant cells and PIK3CA mutant cells co-exist in similar numbers. Finally,
the specific mutant PIK3CA alleles identified in resected human CCM lesions closely
mirrored those identified in human cancers in the COSMIC database (Fig. 2c), consistent
with a shared molecular and cellular mechanism.
2.7 PIK3CA and CCM gene somatic mutations arise in the same cell in human
CCMs
The identification of both PIK3CA and CCM gene somatic mutations in human
CCMs raises a critical mechanistic question: do these mutations occur in the same cell, or
are these mutations in two distinct clonal populations that interact to form a CCM? To
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address this question we next performed single-nucleus DNA sequencing (snDNA-seq) on
3 sporadic and 2 familial CCMs using the Tapestri platform 104. Nuclei isolated from frozen
tissue were stained with DAPI and subjected to fluorescence-activated nucleus sorting
(FANS) to isolate single nuclei that were partitioned into droplets and used as template for
PCR amplification of the exons encoding KRIT1, CCM2, PDCD10, and PIK3CA (Fig. 2d
and Extended Data Fig. 7b-e). Bulk sequencing of sporadic CCM sample 5003 had already
identified one somatic mutation in PIK3CA and two somatic mutations in KRIT1. The same
somatic mutations were identified in the snDNA-seq data and further revealed that the
majority of mutant nuclei harbored all three mutations. In sporadic CCMs, 5038 and 5079,
only one somatic CCM gene mutation was identified in addition to the PIK3CA somatic
mutation. In sample 5079 the second somatic CCM gene mutation is clearly present in total
reads, however due to poor efficiency of the amplicon there were insufficient reads per
nuclei to reliably establish cellular phase with the other two mutations. Data from both of
these samples revealed that the majority of mutant cells harbored both the somatic PIK3CA
and CCM gene mutations. Likewise, snDNA-seq data for familial CCMs, 5065 and 5073,
demonstrated that a majority of somatic mutant nuclei harbored both the PIK3CA mutation
and both CCM gene mutations (Fig 2e, Extended Data Fig. 7f). While the majority of
somatic mutant nuclei in all 5 samples harbored all of the identified somatic mutations,
there was a smaller number of nuclei observed with each possible combination of
genotypes. This observation is unlikely to reflect true cellular variants, as the creation of
cells with all genotypes would require identical somatic mutations to occur in multiple
clonal populations within the CCM lesion. Some of the observed genotype combinations
may represent intermediate clonal populations that formed prior to acquiring the full set of
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mutations, but it is more likely that the majority of these genotype combinations reflect
allelic dropout (ADO) – a common technical artifact in single-nucleus/cell DNA
sequencing data that has been noted in many previous studies104-106. To estimate the rate of
ADO for each sample we identified heterozygous SNPs called in the snDNA-seq data and
evaluated the ratio of heterozygous to homozygous nuclei. This method determined the
rate of ADO to be 8.4% ± 4.1%. We also observed dropout of the constitutional (i.e.
germline) CCM pathogenic allele manifested by the presence of WT nuclei in familial
CCM samples 5065 and 5073. As a result of ADO, the number of nuclei with all somatic
mutations is likely underestimated in each sample. Despite the confounding effects of
ADO, snDNA-seq of all 5 samples clearly indicates that the PIK3CA and CCM gene
somatic mutations arise in the same cell in human CCMs. These human findings confirm
the synergy observed between CCM loss of function and PIK3CA gain of function during
CCM formation in mice, and reveal the existence of a more complex, compound genetic
mechanism for CCM disease similar to that established for cancer.
2.8 CCM LOF and PIK3CA GOF activate mTOR
How do CCM loss of function and PIK3CA gain of function interact to drive CCM
formation? The single cell sequencing studies described above demonstrate that these
mutations arise in the same cell during human lesion formation, consistent with a cell
autonomous interaction. The specificity of the association between PIK3CA gain of
function mutations and CCM loss of function mutations observed in human CCMs, the
strong synergy observed in neonatal and adult mouse models, and the fact that either alone
confers a similar venous vascular lesion in the neonatal hindbrain suggested that the CCM
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and PI3K pathways are likely to intersect through a common molecular effector than
through entirely discrete molecular or cellular mechanisms. A primary mechanism by
which loss of CCM function promotes lesion formation is through gain of MEKK3 activity
and increased expression of KLF2 and KLF4 transcription factors in endothelial cells
35,48,76,94

. Since either CCM loss of function or PIK3CA gain of function alone is sufficient

to drive formation of dilated venous vessels of the white matter (Extended Data Fig. 2), we
first addressed whether PIK3CA gain of function might also induce MEKK3 activity and
an increase in KLF2 and KLF4 expression in neonatal brain endothelial cells (Extended
Data Fig. 8a). Consistent with prior studies, immunostaining of lesional endothelium and
qPCR analysis of brain endothelial cells isolated from P6 Krit1BECKO animals with a
susceptible gut microbiome exhibited high KLF4 protein and Klf4 mRNA expression
(Extended Data Fig. 8b, c). In contrast, the endothelial cells lining vascular lesions or
isolated from P6 Pik3caiBECGOF hindbrains did not express elevated levels of KLF4 protein
or mRNA (Extended Data Fig. 8b, c). Knockdown of CCM genes in cultured human
umbilical vein endothelial cells (HUVECs) confers an increase in KLF2 and KLF4 gene
expression (Extended Data Fig. 8d and

35,76

). In contrast, forced expression of PIK3CA

H1047R using lentiviral vectors did not increase expression of KLF2 or KLF4 in HUVECs
(Extended Data Fig. 8d). These studies suggest that increased KLF2 and KLF4 expression
results primarily from CCM loss of function and MEKK3 gain of function, and that PI3K
signaling is unlikely to act upstream of the MEKK3-KLF2/4 pathway.
PI3K signaling is tightly linked to the activation of mTORC1, a protein kinase
complex that acts as a master regulator of cellular anabolism and growth 107. Since CCMs
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arise in veins where PIK3CA gain of function is known to confer malformations that
respond to the mTORC1 inhibitor Rapamycin 56,59-62,87, we next assessed whether the two
pathways might intersect at the level of PI3K and mTORC1 signaling (i.e. a downstream
mechanism, Fig. 3a). To this end, we measured the phosphorylation of ribosomal protein
S6 (S6), a downstream effector and surrogate reporter of mTORC1 activity that is
amenable to immunostaining. Labeling neonatal Pik3caiBECGOF brain sections with
antibodies specific for the S6 phosphorylation sites serine 235/236 revealed high phosphoS6 levels in endothelial cells lining venous lesions, as expected (Fig. 3a). Strikingly,
immunostaining also revealed elevated phospho-S6 levels in the endothelial cells lining
CCM lesions in the white matter of P6 Krit1BECKO brains (Fig. 3a). This finding was
confirmed by immunoblotting of isolated P6 Krit1BECKO and control brain endothelial cells
showing elevated S6 phosphorylation at Ser235/236 and Ser240/244 (Fig. 3b, c). siRNAmediated loss of CCM function in cultured endothelial cells conferred increases in
phospho-S6 similar to those detected in primary brain endothelial cells (Fig. 3d, e). In
contrast to phospho-S6, significant changes in phospho-AKT were not detected in P6
Krit1BECKO brain endothelial cells or cultured endothelial cells exposed to KRIT1 siRNA
(Fig. 3b-e). These studies reveal that CCM loss of function augments mTORC1 activity in
endothelial cells, and identifies downstream PI3K signaling as a likely point of
convergence between CCM loss of function and PIK3CA gain of function during vascular
malformation.
2.9 KLF4 augments endothelial PI3K-mTOR signaling
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Prior studies have identified increased brain endothelial expression of KLF4 as
causal downstream effector mechanism of CCM formation in vivo35,76,94. To further
address the relationship between CCM loss of function and PI3K signaling, we next used
mouse genetic models to determine whether and how gain of KLF4 interacts with PI3K
signaling in brain endothelial cells in vivo. Using a tetOn-KLF4 allele108, KLF4 expression
was induced in Slco1c1(BAC)-Cre; R26-LSL-rtTA;tetOn-KLF4 (hereafter termed
KLF4iBECGOF for inducible Brain Endothelial Cell Gain Of Function) animals by
doxycycline administration starting at P1 (Extended Data Fig. 9a). Induction of KLF4
expression in KLF4iBECGOF animals resulted in the formation of vascular lesions associated
with peri-lesional hemorrhage by P6 (Fig. 3f and Extended Data Fig. 9b). Similar to the
vascular lesions conferred in neonatal animals by both loss of CCM function and gain of
PIK3CA function, lesions in KLF4iBECGOF animals arose primarily in the veins and postcapillary venules of the white matter (Extended Data Fig. 9c). Immunostaining of tissue
sections revealed elevated endothelial phospho-S6 in KLF4iBECGOF animals (Fig. 3g), a
finding similar to that observed in lesional endothelial cells of Krit1BECKO animals (Fig.
3a). To further test the ability of KLF4 to augment PI3K-mTOR signaling we next
expressed a KLF4-GFP fusion protein in cultured endothelial cells using a tetracyclineinducible lentivirus. KLF4-GFP expression was readily detected using anti-KLF4 and antiGFP antibodies and conferred high expression of the known KLF4 target gene eNOS
(Extended Data Fig. 9e). KLF4 expression significantly increased the levels of phosphoS6 in cultured endothelial cells, as observed with loss of CCM function, and also resulted
in significantly elevated phospho-AKT (Fig. 3h, i). These studies - and the Rapamycin
studies described below (Fig. 4) - demonstrate that increased expression of the causal
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downstream CCM effector KLF4 is sufficient to confer white matter venous lesions like
those conferred by loss of CCM function or gain of PI3K function in association with
increased PI3K-mTORC1 signaling.
2.10 Rapamycin prevents CCM formation in mice
The findings that PIK3CA gain of function supports CCM formation in both adult
mice and humans and that both CCM loss of function and KLF4 gain of function increase
endothelial cell phospho-S6 suggested that increased mTOR activity may be required for
CCM formation. Rapamycin (aka Sirolimus) is an FDA-approved mTORC1 inhibitor that
is an effective therapy for venous and lymphatic malformations that arise due to PIK3CA
gain of function mutations identical to those we identified in human CCM lesions (Fig. 2
and 56,59-62,87). We therefore next tested the ability of Rapamycin to prevent CCM formation
in (i) the established neonatal CCM model that lacks PIK3CA gain of function mutations,
(ii) the adult CCM model described above in which combined PIK3CA and CCM
mutations drive the formation of lesions in adult mice that mirror those resected from
human patients both genetically and morphologically (Fig. 3), and (iii) the neonatal model
that expresses the downstream CCM effector KLF4. Krit1 was constitutively deleted in the
brain endothelial cells of neonatal Krit1BECKO animals with a susceptible microbiome, a
single Rapamycin dose (50 micrograms) administered at P2, and assessment of CCM
lesions in the hindbrain performed visually and with blinded microCT volumetric analysis
at P10 (Fig. 4a). Single dose rapamycin treatment reduced lesion formation dramatically,
by approximately 75%, compared with vehicle alone (P<0.001, Fig. 4b, c). As described
above, our studies demonstrate that a majority of surgically resected human CCMs harbor
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both CCM loss of function mutations and PIK3CA gain of mutations (Fig. 2), supporting
a compound genetic and molecular mechanism of CCM formation for aggressive, clinically
symptomatic lesions. To test the ability of Rapamycin to prevent CCM formation arising
from this compound pathogenic mechanism, we next tested its effect in adult mice in which
CCM loss of function and PIK3CA gain of function are simultaneously stimulated by direct
injection of Cre-encoding viral vector into the brain (Fig. 4d). Rapamycin was administered
daily at either low dose (100 micrograms) or high dose (400 micrograms) starting 7 days
after cranial window surgery and viral Cre injection, a timepoint that coincides with the
earliest visual lesion detection of CCM lesions (Extended Data Fig. 5). Both Rapamycin
dosing regimens were well-tolerated and did not alter animal weight or behavior.
Rapamycin treatment had a dramatic effect on CCM lesion formation in this adult model,
with virtual ablation of CCM growth using either low or high dose treatments (Fig. 4e, f
and Extended Data Fig. 10a-d). Rapamycin treatment ablated the increase in phospho-S6
observed in Krit1BECKO brain endothelial cells, but did not reduce the increase in KLF4
expression (Extended Data Fig. 10e-g). Rapamycin treatment also reduced lesion volume
by approximately 68% in KLF4iBECGOF animals (Fig. 4g-i). These concordant findings are
consistent with a mechanism in which S6 activation is downstream of MEKK3-KLF2/4
signaling (Fig. 3j), support a central role for mTOR signaling in CCM pathogenesis, and
identify Rapamycin as a potentially powerful and available drug to treat CCM disease.
2.11 Discussion
This study identifies a powerful synergy between mutations that confer loss of
CCM function and gain of PIK3CA function in both mouse models of CCM disease and a
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majority of resected human CCMs. These findings provide new insight into the
mechanisms underlying the puzzling natural history of this vascular disease, explain why
the disease has not been successfully modeled in mature mice with CCM loss of function
alone, and reveal a compound genetic disease mechanism for vascular malformation that
is highly analogous to that elucidated for human cancer. Translationally, they also provide
strong evidence that approved drugs capable of inhibiting the downstream PI3K effector
mTOR, and perhaps the PI3K pathway generally, may be used to block the growth and
neurologic complications of clinically symptomatic CCM lesions.
The most significant conceptual advance of this study is the discovery of a
compound genetic mechanism of vascular malformation pathogenesis. To date, vascular
malformations have been considered monogenic in origin, due either to bi-allelic loss of
function mutations, e.g. HHT 109, CM-AVM 110, previously CCM 19,74, or mono-allelic gain
of function mutations, e.g. Sturge-Weber syndrome
malformations
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, lymphatic malformations

59

111

, sporadic bAVM

, and blue rubber bleb nevus

112

, venous

46,113-119
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bulk and snDNA seq studies of human CCMs identify a digenic, “triple-hit” mechanism
involving the acquisition of as many as three distinct genetic mutations that culminate in
loss of CCM gene function and gain of PIK3CA function as the basis for rapidly growing,
clinically symptomatic CCMs. The rapid growth of CCM lesions after both CCM loss of
function and PIK3CA gain of function are present in brain endothelial cells in mice, and
the finding that a majority of mutant cells in human CCM lesions have triple hits, supports
a pathogenesis in which the emergence of a compound mutant endothelial cell enables a
clonal expansion that fuels lesion growth. Thus, aggressive CCM lesions arise via the
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acquisition of multiple somatic mutations that synergize in a manner similar to that of
established cancer drivers. By analogy to cancer, the CCM genes may be considered
vascular “suppressor genes”, required to constrain vessel growth, while PIK3CA may be
considered a vascular “oncogene”, capable of driving excess vascular growth. As in cancer,
the combined loss of a vascular suppressor and gain of a vascular activator is a potent
combination that culminates in aggressive, symptomatic disease. Significantly, the present
study demonstrates that either CCM loss of function or PIK3CA gain of function alone are
sufficient to confer a vascular phenotype that is less aggressive. Analogous to benign
tumors, these lesions only become malignant after mutation of another driver gene, a
scenario consistent with clinical reports of sudden aggressive growth in small, pre-existing
CCM lesions. Whether distinct synergistic driver gene combinations underlie other
vascular malformations is an important future question that may be addressed by deeper
genomic sequencing of human vascular malformations.
A clinical clue to the pathogenesis of human CCM disease that may be explained
by our findings is the observation that sporadic CCMs frequently arise at sites of preexisting developmental venous anomalies (DVAs) (24-32% assessed by MRI, and up to
100% in one surgical assessment79,120,121). Since DVAs are benign and do not undergo
surgical resection, there are no data addressing their genetic basis. However, DVA is found
in a majority of individuals with Cowden syndrome, an inherited disease caused by
germline heterozygous loss of function mutations in PTEN that also result in a gain of PI3K
function

122,123

.

A parsimonious explanation for these clinical observations is that

endothelial cells with pre-existing PIK3CA mutations sufficient to confer DVA
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subsequently acquire CCM loss of function mutations and transform into more aggressive
sporadic CCM lesions. While such a clinical pathogenesis remains entirely speculative
until DVA genetic sequencing is performed, it would support a mechanism highly
analogous to cancer in which accrued mutations convert a benign vascular abnormality into
a more malignant one.
A key question raised by our studies is how CCM loss of function and PIK3CA
gain of function interact at the cellular and molecular levels during lesion genesis. Insights
gleaned from both genetic analysis of human CCM lesions and mouse genetic models are
highly complementary, and support an endothelial cell autonomous mechanism in which
the two pathways may be directly linked. Single cell genomic DNA sequencing of both
sporadic and familial human CCM lesions reveals that a majority of mutant cells harbor
acquired mutations in both a CCM gene and PIK3CA, strong evidence of pathway
interaction at the single cell level and of a growth mechanism in which the majority of
clonal expansion occurs after acquisition of all three mutations. Sporadic lesions arise in
Slco1c1(BAC)-CreERT2;Krit1fl/fl;R26-LSL-Pik3caH1047R animals due to Cre leak that is
exclusively endothelial, identifies the endothelial cell as the target cell type and, like the
human genetic sequencing data, is suggestive of a clonal mechanism in which emergence
of a single compound mutant endothelial cell is sufficient for lesion formation. Consistent
with these data supportive of endothelial cell autonomy, both loss of CCM function and
gain of KLF4 function boost PI3K-mTORC1 signaling in both brain endothelial cells in
vivo and cultured endothelial cells ex vivo. These findings are consistent with the potent
effect of Rapamycin in preventing CCM lesion formation, with prior studies in cultured
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endothelial cells demonstrating that KRIT1 loss of function stimulates mTOR and
interferes with autophagy 124, and with a prior pharmacologic screen for pathways involved
in CCM pathogenesis 125. Convergence of the two pathways at PI3K and mTOR signaling
explains the similar venous phenotypes conferred by CCM loss of function or PIK3CA
gain of function alone in the neonatal hindbrain, as well as the exquisite sensitivity of CCM
formation to mTORC1 inhibition in vivo, and suggests that a threshold level of PI3KmTOR signaling is required to trigger CCM lesion formation. The observation that KLF4
gain of function is sufficient to confer CCM-like lesions that are also suppressed by
Rapamycin further suggests that CCM-MEKK3-KLF2/4 signaling regulates PI3K-mTOR
signaling through a cell autonomous transcriptional mechanism, but this hypothesis
remains to be tested. While other molecular mechanisms linking CCM signaling and PI3KmTOR signaling in endothelial cells are likely to exist, these studies support a mechanism
of disease pathogenesis in which linear, cell autonomous augmentation of PI3K-mTOR
signaling plays a central role in lesion growth.
Immediately translatable findings of this study are that PIK3CA gain of function
plays a causal role in the growth of clinically symptomatic, aggressive CCM lesions, and
that mTORC1 inhibition using an approved drug may slow or arrest this growth. We
observe a remarkable sensitivity of CCM growth to Rapamycin, especially in the adult
mouse model that combines CCM loss of function and PIK3CA gain of function in a
manner that most faithfully reflects human CCM lesions at both the genetic and
morphologic levels. Although aggressive CCM lesions are relatively rare, they account for
virtually all of the strokes and neurologic symptoms associated with this disease, and they
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can presently only be treated by surgical resection. Sirolimus has recently been used
successfully to treat lymphatic and venous/slow flow vascular malformations that are
associated with identical PIK3CA gain of function mutations

126-130

, and newer agents

directly targeting PIK3CA itself have also been found to be effective for treatment of
inoperable vascular malformations associated with PIK3CA gain of function mutations 64.
It is reasonable to predict that Rapamycin-type drugs and newer agents designed to block
the PI3K pathway will be effective when administered to patients with aggressive CCM
lesions. Whether all rapidly growing lesions harbor both CCM loss of function and
PIK3CA gain of function mutations, and therefore might be predicted to be sensitive to
mTORC1 inhibition, is not yet clear. The inability to detect both homozygous CCM loss
of function and PIK3CA gain of function mutations in many resected human lesions is
likely due to the presence of somatic mutations such as large deletions and chromosomal
loss of heterozygosity that are not detectable by targeted short-read sequencing but may
account for a substantial fraction of CCM loss of function events, as is the case in cancer
131,132

. An additional confounder may be an insufficient limit of detection of targeted

sequencing for identifying mutations in the low fraction of total genomic DNA that derives
from lesional endothelium in the surgically resected CCM lesion samples analyzed.
Alternatively, it may indicate the presence of distinct, yet to be identified pathways that
drive a similar phenotype. Further sequencing of human CCM lesions and clinical testing
of Sirolimus and other PI3K pathway blocking drugs will determine whether this
mechanism and potential therapeutic strategy can be applied widely to the treatment of
CCM disease.
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2.12 Materials and Methods
1) Mice
Cdh5–CreERT2 (ref. 133), Slco1c1(BAC)–Cre (ref.134), Slco1c1(BAC)–CreERT2 (ref.134),
Pdgfb–CreERT2 (ref.135), Krit1fl/fl (ref.
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), tetOn–KLF4 (ref.

108

) and Ptenfl/fl (ref.136)

animals have been described previously. R26–nTnG (JAX, catalogue number 023035) and
R26–LSL–Pik3caH1047R (JAX catalogue number 016977 and ref.

101

) animals were

obtained from the Jackson Laboratories. R26–CAGs–LSL–rtTA3 mice (JAX catalogue
number 029617) were provided by Lukas Dow. All experimental animals were maintained
on a mixed-strain background, and littermate controls were used for neonatal experiments
unless otherwise indicated. Breeding pairs between two and eight months of age were used
to generate neonatal CCM mouse models of the indicated genotypes. Sample size was
determined from prior studies using similar animals and techniques.
For all neonatal CCM experiments using the Cdh5–CreERT2;Krit1fl/fl (Krit1iECKO),
Slco1c1(BAC)–CreERT2;Krit1fl/fl

(Krit1iBECKO)

and

Slco1c1(BAC)–Cre;Krit1fl/fl

(Krit1BECKO) models, P1 pups were injected intragastrically using a 30-gauge needle with
40 μg of 4-hydroxytamoxifen (4OHT, Sigma Aldrich catalogue number H7904) dissolved
in 9% ethanol/corn oil vehicle (total volume 50 μl per injection). The solution was freshly
prepared from premeasured, 4OHT powder for every injection. The P1 time point was
defined by checking experimental breeding pairs every evening for new litters. The
following morning (P1), pups were injected with 4OHT in a blinded fashion without
knowledge of genotypes. Pups were then harvested, as described35, at specified time points.
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For adult CCM deletion experiments using littermate Cdh5–CreERT2;Krit1fl/fl (Krit1iECKO)
animals, tamoxifen (Sigma Aldrich, T564) was dissolved in a 100% corn oil vehicle. The
solution was freshly prepared for every gavage. Male mice were given 3 mg tamoxifen via
gavage beginning at two months of age, twice a week for three weeks, for a total of six
gavages, then placed on tamoxifen chow diet (Envigo, catalogue number TD.160410) until
harvested at six months of age.
For craniotomy experiments, we used adult mice of the genotypes Krit1fl/fl, Krit1fl/+;R26–
LSL–Pik3caH1047R or Krit1fl/fl; R26–LSL–Pik3caH1047R, of either gender, at between six and
ten weeks of age.
For KLF4 GOF experiments using Slco1c1(BAC) –Cre; R26–LSL–rtTA;tetO–KLF4
(KLF4iBECGOF) animals, P1 pups were intragastrically injected using a 31G insulin syringe
with 200 μg of doxycycline (Sigma-Aldrich, D9891) dissolved in phosphate-buffered
saline (PBS; total volume 20 μl per injection). Pups were harvested at P6 unless otherwise
indicated.
All mice were housed in individual, ventilated cages with 12-h light/dark cycles, with food
and water ad libitum. All animals were housed in a pathogen-free environment in a
vivarium approved by the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC) at the University of Pennsylvania; experiments were performed
in accordance with the guidelines of the Institutional Animal Care and Use Committee
(IACUC).
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2) In Vivo Experiments
X-ray microCT-based quantification of CCMs
For all experiments using microCT quantification of CCM lesion volume, brains were
harvested and placed in 4% PFA/PBS. Brains remained in fixative until staining with nondestructive iodine contrast, and subsequent microCT imaging was performed as
described46. Tissue processing, imaging, and volume quantification were performed in a
blinded manner by investigators at the University of Chicago without any knowledge of
genotype and experimental details.

Craniotomy survival surgery
Animals were anaesthetized with isoflurane (3% induction, 1–2% maintenance in 1 l min−1
oxygen) for surgery. Mice were placed on a heating pad covered with a cotton pad to
maintain a body temperature of 37.5 °C. The depth of anaesthesia was periodically
monitored by testing the animal’s reflexes through toe pinch. Eyes were covered with
ophthalmic lubricant to prevent drying. A stereotactic frame (Stoeling Instruments) was
used to immobilize the head using ear bars. All mice receiving craniotomies also received
1.5 mg kg−1 of dexamethasone intramuscularly (Sigma) and 5 mg kg−1 of 10% meloxicam
(Midwest Vet Supply) subcutaneously.
After the head was immobilized, hair on the scalp was removed with Nair. The scalp was
subsequently cleaned and sterilized with 70% ethanol and betadine at least three times. A
midline scalp incision was made and resected to expose the skull. The periosteum was
removed with blunt forceps. The outer table of the skull was thinned using a handheld high41

speed dental drill (Foredom) using a 0.5 mm burr. In the adult mice, a 3–4 mm2
circumferential region was chosen over the right somatosensory cortex posterior to the
coronal suture. Sterile saline was used to irrigate the drill burr to prevent build-up of bone
residue and heating of the drill bit. Gelfoam in sterile saline was used to provide
haemostasis and to remove bone dust. The border of the craniotomy was thinned until the
inner table fractures. A fine-tip forcep (Fine Science Tools) or an up-angled curette (Fine
Science Tools) was used to lift the bone flap and gently elevate it from the dura. Gelfoam
was used to provide haemostasis and prevent the brain surface from desiccating.
Upon completion of intraparenchymal viral injection, haemostasis was obtained. A cranial
window made from a 0.3 mm coverslip cemented to a 0.5 mm coverslip (Warner) was then
placed over the craniotomy site and secured to the skull using cyanoacrylate glue. A
custom-made imaging rig (3D printed using acrylonitrile butadiene styrene (ABS)) was
then secured over the glass coverslip using cyanoacrylate glue and dental cement
(Metabond).
Post-surgery, adult mice were monitored and kept separately from littermates until awake
and mobile. Mice who developed any postoperative seizures were euthanized. A second
dose of subcutaneous meloxicam was given to mice as necessary on the basis of a second
exam an hour after surgery. Mice were monitored and imaged for up to 21 days after AAV
injection before they were harvested.

AAV injection
Recombinant AAV vectors were donated by J. Körbelin’s laboratory137. AAV–BR1
vectors carrying Cre recombinase under the control of the CAG promoter vector were
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injected into the right lateral hemisphere of mice using a beveled glass micropipette. We
injected 100 nl of 5 × 107 virus particles in sterile PBS over the course of 5 min.

Lineage tracing of AAV–Cre
Mice were housed in individually ventilated Green Line cages (Tecniplast) under a 12-h
light/dark cycle and fed an autoclaved pelleted mouse diet ad libitum. AAV–BR1–CAG–
Cre (2 × 109 genomic particles; 200 nl) was stereotactically injected into the cortex of 12week-old Ai14 mice. Mice were anaesthetized with an intraperitoneal injection of a mixture
of ketamine hydrochloride (65 μg g−1 body weight) and xylazine (15 μg g−1 body weight)
in NaCl (0.9%). After loss of reflexes, animals were fixed in a stereotaxic frame (David
Kopf instruments; Nr: 1900). The following coordinates relative to bregma were used for
injections: anteroposterior −1.5 mm, mediolateral −0.75 mm, dorsoventral from the skull
surface −2.0 mm. A small hole was made into the skull using a dental drill (Foredom;
K.1070 Micromotor Kit). After injection, the micropipette was kept in place for 5 min to
avoid backflow of the injected vector during micropipette retraction. The scalp was
sutured, and the animals were placed on a heating pad until full recovery from surgery and
then returned to their home cage. Carprofen (5 mg kg−1 body weight) was applied
subcutaneously once a day for two days after injection of the recombinant AAV.
Two weeks after viral injection, mice were perfused with Ringer’s solution and then with
4% PFA during deep aesthesia. Brains were postfixed in 4% PFA at 4 °C overnight.
Sections (50 μm) were prepared with a vibratome. Free-floating sections were washed
twice in PBS, permeabilized with 0.3% Triton X-100 in PBS (PBS-TX) for 30 min, and
incubated in BSA (5% in PBS-TX) for 2 h. Primary antibodies (anti-CD31, BioRad
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(catalogue number MCA2388), dilution 1:200 (5 μg ml−1) in BSA-PBS-TX) were added,
followed by overnight incubation with gently shaking. Sections were washed twice in PBSTX for 10 min and incubated for 2 h with secondary antibodies (anti-rat IgG (Alexa Fluor
488), ThermoFisher (A-21208), 1:400 (5 μg ml−1) in BSA-PBS-TX). After washing twice
in PBS, sections were incubated with DAPI (1 μg ml−1 in PBS) for 5 min and washed twice
in PBS for 5 min. Sections were mounted on glass slides and covered with Mowiol.

Rapamycin injection
Rapamycin (MedChemExpress, HY-10219) was dissolved in DMSO to generate a
10 mg ml−1 stock solution and diluted in sterile PBS to generate a 1 mg ml−1 working
solution. Slco1c1(BAC)–Cre;Krit1fl/fl littermate pups were injected intraperitoneally at P2
with either 50 mg of rapamycin (volume of 50 ml) or vehicle and harvested at P10.
For experiments in which adult mice were treated with rapamycin, either drug or vehicle
was administered to adult Krit1fl/fl;R26–LSL–Pik3caH1047R mice who underwent open
craniotomy and injected with AAV–Cre. We dissolved 50 mg of rapamycin powder in 1 ml
100% ethanol to create a stock solution, of which 1 mg was freshly prepared in 5% DMSO
in sterile PBS for every injection. Intraperitoneal injections of either rapamycin or vehicle
(5% DMSO) began on post-operative day 7, when nascent cavernoma lesions could be
visualized under microscopy. Injections were performed daily within a two-hour window
until animals were harvested on post-operative day 21 at either a low dose (100 μg) or a
high dose (400 μg).
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For experiments involving treating KLF4BECGOF animals with rapamycin, 100 mg of
vehicle or rapamycin was injected intraperitoneally (50 μl total volume) to P10
Slco1c1(BAC)–Cre;R26–LSL–rtTA;tetOn–KLF4 and littermate Slco1c1(BAC)-Cre;R26–
LSL–rtTA pups. To induce KLF4 expression, 400 μg of doxycycline was administered via
oral gavage. Animals were harvested at P14.

Histology, immunohistochemistry, and quantification
Mice were anaesthetized with an intraperitoneal injection of tribromoethanol (Avertin),
followed by intracardial perfusion with 20 ml of cold PBS and 4% (w/v) paraformaldehyde
(PFA) in PBS (pH 7.4) for adult mice and 10 ml respectively for neonates. Tissue samples
were fixed in 4% PFA/PBS overnight at 4 °C, dehydrated to 100% ethanol, and embedded
in paraffin. Tissue sections of 6 μm underwent dewaxing and rehydration through xylene
and ethanol treatment, and were subsequently used for haematoxylin-and-eosin and
immunohistochemistry staining. For immunodetection, 10 mM citrate buffer (pH 6)
(Sigma, catalogue number C9999) was used for antigen retrieval, and sections were
blocked with 10% donkey serum in 1% bovine serum albumin (BSA) before primary
antibody treatment overnight at 4 °C. The following primary antibodies were used for
immunostaining: rat anti-PECAM1/CD31 (1:200 dilution; HistoBioTec, DIA-310), goat
anti-KLF4 (1:100; R&D Systems, AF3158), goat anti-GFP (1:100; Rockland
Immunochemicals, 600-101-215), rabbit anti-ERG (1:100; Abcam, ab110639), and rabbit
anti-phospho-S6 (1:200, Cell Signaling Technologies, 4858S). Fluorescence-conjugated
Alexa Fluor secondary antibodies were used (1:500, Invitrogen) according to the primary
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antibody species and counterstained with DAPI (1:1,000). Secondary antibodies were
validated for nonspecific staining by no primary antibody negative controls.
Control and experimental animal sections were stained at the same time under identical
conditions. Sections were mounted on slides with ProLong Gold Antifade reagent. Images
were acquired on a Nikon 80i Eclipse, an Olympus DP80 microscope, and/or a Zeiss LSM
710 or Zeiss 880 confocal microscope at the same exposure times, using ×4, ×10, ×20 and
×40 objectives, and subsequently processed in ImageJ software (National Institutes of
Health, NIH).
Quantification for the R26–nTnG leak experiment was done by counting the number of
nuclear GFP (nGFP)-positive, ERG-positive endothelial cells compared with the total
number of ERG-positive cells present within a lesion. Twenty random 800 mm × 800 mm
fields, from three unique individual animals, were assessed.

Isolation of cerebellar endothelial cells
At the specified time points, cerebellar endothelial cells were isolated by mechanical and
enzymatic digestion followed by separation using magnetic-activated cell sorting by antiCD31/PECAM1-conjugated magnetic beads (MACS MS system, Miltenyi Biotec), as
described35.

3) In Vitro Experiments
siRNA knockdown and lentiviral expression
Cell culture. Pooled HUVECs were purchased from Lonza (catalogue number CC- 5 2519)
and cultured in endothelial basal medium (EBM, Lonza) supplemented with
46

hydrocortisone (1 μg ml−1), bovine brain extract (12 μg ml−1), gentamicin (50 μg ml−1),
human recombinant epidermal growth factor (10 ng ml−1), and 10% fetal bovine serum
(FBS, Life Technologies). HUVECs were tested negative for mycoplasma and cultured
until the fourth passage. Cells were maintained at 37 °C in a humidified atmosphere with
5% CO2.
Small interfering RNAs, lentiviral expression and qPCR. Small interfering RNAs directed
against KRIT1 (s2510, Invitrogen) were used for knockdown experiments at a
concentration of 10 nM. For overexpression studies, HUVECs were infected with a control
lentivirus encoding either GFP or mutant human PIK3CA with the H1047R mutation
(constructed from pBabe puro haemagglutinin-tagged PIK3CA H1047R from J. Zhao
(Addgene plasmid 12524). Cells were harvested 48 h post-infection or post-transfection
and total RNA was isolated using TRIzol reagent (Life Technologies). Complementary
DNA was generated from 500 ng total RNA using the SuperScript IV VILO master mix
(Thermo Fisher, 11756050) and real-time qPCR was performed using Power SYBR Green
PCR master mix (Applied Biosciences). Protein was harvested with RIPA buffer with
complete protease-inhibitor cocktail (Roche) and PhosSTOP phosphatase-inhibitor
cocktail (Roche).
Human primers. Primers are as follows:
GAPDH forward: 5′-CTGGGCTACACTGAGCACC-3′;
GAPDH reverse: 5′-AAGTGGTCGTTGAGGGCAATG-3′;
KLF2 forward: 5′-CTACACCAAGAGTTCGCATCTG-3′;
KLF2 reverse: 5′-CCGTGTGCTTTCGGTAGTG-3′;
KLF4 forward: 5′-AGAGTTCCCATCTCAAGGCA-3′;
KLF4 reverse: 5′-GTCAGTTCATCTGAGCGGG-3′;
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PIK3CA forward: 5′-CCACGACCATCATCAGGTGAA-3′;
PIK3CA reverse: 5′-CCTCACGGAGGCATTCTAAAGT-3′.
Lentivirus generation, production, and infection
For doxycycline-inducible lentiviral expression of a human GFP-tagged KLF4 (isoform 1),
cDNA was cloned into pLVX–TetOne–Puro (Clontech). Virus production was performed
by co-transfecting pMD2.G (Addgene, 12259), psPAX2 (Addgene, 12260) and transfer
plasmids into HEK293FT cells. Transfections were performed with lipofectamine 2000
transfection reagent (Life Technologies) according to the manufacturer’s instructions.
Viruses were harvested after 24 h and 48 h and then incubated with HUVECs for 16 h in
the presence of 8 μg ml−1 polybrene (Santa Cruz Biotechnology, SC-134220). Fresh EBM
media containing 1 μg ml−1 puromycin (InvivoGen, ant-pr-1) was added to select
transduced cells. To induce KLF4 expression, selected cells were treated with 300 ng ml−1
doxycycline for 72 h before harvesting. Lentiviruses encoding GFP were used as a control.

Gene expression in isolated endothelial cells
Total RNA was extracted from isolated endothelial cells using the RNEasy mini kit
(Qiagen) and reverse transcribed using the SuperScript IV VILO master mix (Thermo
Fisher, 11756050). To quantify levels of transcript expression, real-time PCR was
performed using Power SYBR Green PCR master mix (Thermo Fisher, 4368577). Relative
gene expression was normalized to Gapdh levels and calculated using the ddCt method.
Mouse primers. Primers are as follows:
Gapdh forward: 5′-AAATGGTGAAGGTCGGTGTGAACG-3′;
Gapdh reverse: 5′-ATCTCCACTTTGCCACTGC-3′;
Klf2 forward: 5′-CGCCTCGGGTTCATTTC-3′;
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Klf2 reverse: 5′-AGCCTATCTTGCCGTCCTTT-3′;
Klf4 forward: 5′-GTGCCCCGACTAACCGTTG-3′;
Klf4 reverse: 5′-GTCGTTGAACTCCTCGGTCT-3′;
Pik3ca forward: 5′- CCACGACCATCTTCGGGTG-3′;
Pik3ca reverse: 5′- GGGGAGTAAACATTCCACTAGGA-3′.
Protein immunoblotting
Western blot analyses were performed with precast gradient gels (BioRad) using standard
methods. Briefly, HUVECs were lysed in RIPA buffer (Sigma; 150 mM NaCl, 1.0% (v/v)
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris, pH 8.0)
supplemented with 1 × EDTA-free complete protease-inhibitor cocktail (Roche) and 1 mM
phenylmethylsulfonyl fluoride. Proteins were separated by SDS–PAGE (Tris-glycine gels
with Tris/glycine/SDS buffer; BioRad) and transferred onto nitrocellulose membranes
using the trans turbo blot system (BioRad). Membranes were probed with specific primary
antibodies and then with peroxidase-conjugated secondary antibodies. The following
antibodies were used for immunoblotting: rabbit anti-GAPDH (1:2,000, Cell Signaling
Technologies, 2118), rabbit anti-phospho-AKT Ser 473 (1:1,000, Cell Signaling
Technologies, 4060), rabbit anti-phospho-S6 Ser 235/236 (1:1,000, Cell Signaling
Technologies, 4858), mouse anti-total AKT (1:1,000, Cell Signaling Technologies, 2920)
and mouse anti-total S6 (1:1,000, Cell Signaling Technologies, 2317). For the
immunoblots shown, antibodies to the following proteins were used: eNOS (Cell Signaling
Technology, 9586, 1:1,000), GFP (Cell Signaling Technology, 2555, 1:5,000), KLF4 (Cell
Signaling Technology, 4038, 1:1,000), phospho-S6 (Ser 235/236) ribosomal protein (Cell
Signaling Technology, 4857, 1:4,000), phospho-S6 (Ser 240/244) ribosomal protein (Cell
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Signaling Technology, 2215, 1:4,000), S6 ribosomal protein (Cell Signaling Technology,
2217, 1:4,000), phospho-AKT (Ser 473) (Cell Signaling Technology, 4060, 1:2,000),
phospho-AKT (Thr 308) (Cell Signaling Technology, 4056, 1:1,000), AKT (pan) (Cell
Signaling Technology, 4685, 1:2,000), Tubulin (Cell Signaling Technology, 2148,
1:5,000). Secondary antibodies are peroxidase-conjugated goat IgGs (1:5,000) purchased
from Jackson Immuno Research Labs. Quantification was normalized to total protein.
Imaging was performed on a Licor Odyssey FC system and quantified using ImageStudio
software.

4) Human Genetics
Collection of human CCMs
Human CCM tissue specimens were obtained from surgically resected specimens from
three sources: the Barrow Neurological Institute, Angioma Alliance Biobank, and
University of Chicago. This study was approved by each institution’s Institutional Review
Board.

Collection of human brain AVMs
Brain AVM tissue specimens were obtained from the nidal tissue of surgically resected
brain AVMs (medial temporal lobe). For nonvascular lesion controls (NVLCs), temporal
lobe specimens were similarly acquired from subjects undergoing anterior temporal
lobectomies for medically refractory epilepsy. All tissues were frozen at −80 °C and stored
in a biobank. This study was approved by the University of California San Francisco
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Institutional Review Board and performed in compliance with the Health Insurance
Portability and Accountability Act regulations.

DNA extraction
DNA from human CCM samples was extracted using a DNeasy blood and tissue kit
(Qiagen). Extractions were carried out as per the manufacturer’s directions, except in cases
in which less than 25 mg of tissue was available. For samples of less than 25 mg, the
manufacturer-recommended volumes were either halved or quartered—depending on the
amount of tissue available—to optimize the final DNA concentration and yield. Final DNA
concentrations were quantified using a Qubit dsDNA BR assay kit (Invitrogen, catalogue
number Q32850) according to the manufacturer’s protocol.
Droplet digital PCR
Somatic PIK3CA mutations were identified using droplet digital PCR (ddPCR) according
to the manufacturer’s protocol for mutation detection assays (BioRad, catalogue number
10047489 version B). For each sample with sufficient DNA yield, 30–100 ng of DNA was
incorporated into droplets using a QX200 AutoDG system (BioRad). After PCR,
fluorescence from the resulting droplets was read using a QX200 droplet reader (BioRad).
These steps were repeated for three assays to test for the presence of the three most common
PIK3CA mutations, E542K, E545K and H1047 (ThermoFisher assay identification
numbers Hs000000085_rm, Hs000000086_rm and Hs000000088_rm, respectively). Each
assay included a no-template control, a wild-type control, and a mutation-positive control
for the mutation being assayed. The mutation-positive controls comprised DNA extracted
from cell lines with known heterozygous mutations of E542K (T84), E545K (HCT15) or
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H1047R (HCT116). The output of the droplet reader was analysed using QuantaSoft
software (BioRad). The gates for positive and negative mutation status were drawn with
respect to the distribution of droplets in the mutation-positive controls and applied to all
samples.
SNaPshot
Human CCM samples with an E542K, E545K or H1047R PIK3CA mutation identified by
sequencing or ddPCR underwent tertiary confirmation of mutation status using SNaPshot
(Applied Biosystems), a single-base extension Sanger sequencing assay. An initial round
of PCR amplified exons 9 and 20. In a second round of PCR, primers directly adjacent to
the assayed nucleotide were extended with ddNTPs and sequenced on a 3130 Genetic
Analyzer (Applied Biosystems). Sequences were examined using GeneMapper software
(Applied Biosystems). The allele frequency of the mutation was obtained by dividing the
area under the peak of the mutant allele by the total area under both allele peaks. primers
were synthesized according to designs in a previously published assay for PIK3CA
mutations138.
Sequencing
Previous studies identifying somatic mutations in CCMs and bAVMs have reported
alternate allele frequencies of less than 1%. To enable the detection of variants at such low
frequencies, we aimed to sequence samples to an average coverage of 1,000× (actual mean
coverage 1,102×) and to leverage 10-bp unique molecular identifiers (UMIs) to mitigate
the impact of PCR duplication. Theoretically, we can thereby detect variants with allele
frequencies as low as 0.5%.
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Sequencing libraries for the human CCMs and bAVMs were prepared using the SureSelect
XT HS target-enrichment workflow (Agilent). The targeting panel used for sequencing the
CCMs covers the following genes: KRIT1, CCM2, PDCD10, PIK3CA, PTEN, AKT1,
KRAS, RAF, NRAS, MAP2K1, RASA1, TEK, GNAQ, GNA11, MAP2K2, PPP2R5D,
ACVRL1, ENG, SMAD4, AKT2, AKT3, CCBE1, CDKN1C, FLT1, FLT4, FOXC2, GATA2,
GDF2, GJC2, GLMN, KIF11, MTOR, PIK3R2, PTPN14, SOX18, STAMBP, VEGFC,
MAP2K4, MAP3K1, MAPK1, JAK1, JAK2, JAK3, KDR, NOTCH1, PDGFRA, PDGFRB,
RET, HRAS, TP53, MSH2, MYB, MYCN, MYC, ERBB2, EGFR, NTRK2, ODC1,
SLC25A21, PTTG1, TSC1, TSC2, EPHB2, TGFBR1, TGFBR2 and TGFBR3.
The bAVM samples were sequenced using a customized Agilent comprehensive cancer
panel which covers 175 genes, including PIK3CA. After library preparation, CCM samples
were pooled and sequenced across one lane of a HiSeq4000 (Illumina) with paired-end
150-bp reads. bAVM samples were pooled and sequenced across a NovaSeq6000 SP flow
cell (Illumina) with paired-end 150-bp reads.

Sequence analysis
Sequencing data were processed according to the Gene Analysis Toolkit (GATK, Broad
Institute) best practices for somatic short variant discovery, with slight modifications for
‘tumour-only’ sequencing data. As a secondary method for variant discovery, we
developed custom software designed specifically to detect somatic mutations in sequencing
data from samples with no available normal tissue. This software was implemented as part
of Gonomics, an ongoing effort to develop an open-source genomics platform in the Go
programming language. Gonomics can be accessed at github.com/vertgenlab/gonomics.
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After variant calling, the resulting variants were functionally annotated using snpEff
(https://pcingola.github.io/SnpEff/). In this process, each variant was annotated with: the
protein-level consequence of coding mutations; the predicted impact of missense mutations
according to SIFT, PolyPhen2 and PROVEAN; membership in several SNP databases
including dbSNP, 1000 Genomes project, and ExAC; and membership in the Catalogue of
Somatic Mutations in Cancer (COSMIC). We filtered the resulting list of variants using
the following inclusion criteria: greater than 100× total coverage; more than five supporting
reads; less than 90% strand specificity; greater than 0.5% alternate allele frequency; less
than 1% population allele frequency, according to the aforementioned SNP databases; and
membership in the COSMIC database.

Single-nucleus DNA sequencing
Frozen human CCM tissues obtained from medically indicated, surgical resection were
prepared for snDNA-seq according to a nuclear-isolation protocol provided by L.
Martelotto. All steps before loading on the Tapestri platform were performed in less than
3 h. Nuclei were maintained at 4 °C throughout the protocol. Frozen tissue was
homogenized by Dounce in Nuclei EZ lysis buffer (Sigma-Aldrich), briefly washed,
filtered through a 70-mm mesh, stained with DAPI, and filtered through a 35-mm mesh.
The CCM homogenate was sorted using a FACSAriaII (BD) (70-mm nozzle, 70 psi, fourway purity, chiller), gating in order to retain singlet DAPI-positive events (Extended Data
Fig. 7b). Up to 400,000 sorted nuclei were collected in 1 ml of the following buffer,
prepared with ultrapure nuclease-free water: 82 mM Na2SO4, 30 mM K2SO4, 10 mM
glucose, 10 mM HEPES, 5 mM MgCl2•6H2O and 2% BSA 2%. Sorted nuclei were
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pelleted by centrifugation at 4 °C (relative centrifugal force 500, 10 min), the supernatant
discarded, and resuspended in 36 ml of MissionBio cell buffer. The concentration of nuclei
was determined by counting DAPI-positive nuclei with a haemocytometer on an EVOS FL
(fluorescence) microscope (Thermo Fisher) while confirming that nuclei aggregates
comprised less than 5% of total nuclei. Samples with less than 5% aggregate nuclei and a
concentration of 2,000–4,000 nuclei per microlitre (diluting with additional MissionBio
Cell Buffer where necessary) were used for snDNA-seq.
Libraries were prepared using the Tapestri platform (MissionBio) according to the
manufacturer’s protocol (catalogue number PN3354). Libraries were generated with a
custom amplicon panel synthesized by MissionBio, covering all exons of KRIT1, CCM2
and PDCD10 and seven amplicons covering somatic mutation hotspots in PIK3CA, per the
COSMIC database. Up to three libraries were pooled and sequenced with a NextSeq MidOutput 2 × 150 bp kit (illumina). Data processing and quality control were performed using
the MissionBio cloud-based analysis pipeline. Data quality for each nuclei barcode was
determined using MissionBio’s recommended filtering settings. Data from low-quality
nuclei barcodes were removed before mutation analysis. After these filtering steps, the
allele frequencies of mutations detected by snDNA-seq show high concordance with allele
frequencies determined by bulk sequencing (Extended Data Fig. 7c–e).
To determine the cellular phase of somatic mutations detected in bulk sequencing, we
selected nuclei barcodes that had a minimum of 20× coverage across all mutant regions to
ensure that all nuclei included in the analysis have appropriate sensitivity to detect a
mutation (Extended Data Fig. 7c–e). For each nuclei barcode and each mutant position,
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reads containing the reference and alternative alleles were counted and recorded in
Supplementary Table 2. Mutant regions that had both a minimum of 10 alternative reads
and 10% allele frequency were marked as mutation positive. The numbers of nuclei
barcodes with each possible genotype are recorded in Extended Data Fig. 7f.
The P value for each sample was determined by a chi-squared test comparing the observed
number of triple-mutant nuclei barcodes (or double-mutant if only two mutations were
identified) to the number of triple-mutant nuclei barcodes expected if the null hypothesis
were true. In this test, the null hypothesis is that the observed somatic mutations do not
occur in the same cell, and instead exist in two clonal populations where the proportion of
each population is twice the variant allele frequency (assuming that cells are diploid and
heterozygous for the mutation). In samples in which three somatic mutations were
identified, an alternative null hypothesis might be to use three clonal populations; however,
assuming that the three somatic mutations are partitioned into two clonal populations (as
asserted above) is a more conservative test and therefore used here. To determine the
expected number of triple-mutant nuclei barcodes, we first determined the expected
number of droplets with two (or more) nuclei by approximating a Poisson distribution. The
expected number of triple-mutant nuclei barcodes is the product of the number of droplets
with two nuclei, the proportion of mutant clone 1, and the proportion of mutant clone 2.
Here we report the Poisson-estimate P value, as this is the accepted method for
estimating the rates of false-positive droplets when dealing with data generated using
microfluidics. We can also consider a more intuitive upper bound for the P value by
considering the extreme case in which each droplet contains two nuclei. In this case, the
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expected number of triple-mutant nuclei barcodes is the product of the total number of
nuclei barcodes, the proportion of mutant clone 1, and the proportion of mutant clone 2.
Even in this extreme case, the highest P value among our data is less than 1 × 10−17.
Statistics
All neonatal experimental and control animals were littermates, and none was excluded
from analysis at the time of harvest. Experimental animals were excluded at the
predefined point under either of the following conditions: first, failure to properly inject
the inducing agent (4OHT, tamoxifen or rapamycin); and second, observation of
substantial leakage. Sample sizes were estimated based on our previous experience with
the neonatal CCM model and microCT quantification of lesion volume, as described46,77.
All data were analysed with GraphPad Prism software (version 8) and are represented as
means ± s.e.m. P values were calculated using an unpaired two-tailed Welch’s t-test, or
one-way analysis of variance (ANOVA) and Tukey’s test for multiple comparisons as
indicated in the figure legends. A log-rank test was used to assess Kaplan–Meier survival
curves. P values of less than 0.05 were considered statistically significant and are denoted
as follows: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

57

2.12 Figures
Figure 2-1

Figure 2-1 CCM LOF and PIK3CA GOF synergize during cavernous malformation
in the neonatal brain and are both required for malformations in the adult brain.
a, Schematic of neonatal induction of Krit1 deletion and/or PIK3CAH1047R expression. 4hydroxytamoxifen (4OHT) injection at P1 was used to inducibly delete Krit1
(Krit1iBECKO), drive expression of PIK3CAH1047R (Pik3caiBECGOF) or both specifically in
the brain endothelial cells of mice carrying a resistant gut microbiome. b, Representative
visual and microCT images of the indicated P7 brains. Note that loss of KRIT1 alone is
not sufficient for CCM formation in animals with a resistant microbiome. Scale bars,
1mm. c, MicroCT quantitation of lesion volumes at P7. (Krit1iBECKO, n=4; Pik3caiBECGOF,
n=12; Krit1iBECKO;Pik3caiBECGOF , n=6). Indicated p-values are: p=0.0002; p=0.0001;
p=8e-8 (top to bottom). d, Schematic and diagram of the experimental approach in which
a cranial window is created and AAV virus injected into the brains of 2 month old mice
with serial imaging on indicated post-operative days (POD). e, Serial images obtained
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through the same cranial window of Krit1fl/fl;iPik3caH1047R animals following injection of
control or Cre-expressing AAV vectors. Cranial window images representative of 4
animals/group. f, Representative visual and microCT images of brains harvested 21 days
after injection of AAV-Cre into adult animals with the indicated genotypes. iPik3caH1047R
designation includes iPik3caH1047R and/or Krit1fl/+;iPik3caH1047R genotypes. Dotted circles
indicate the site of cranial window and AAV-Cre injection. Scale bars, 1mm. g, MicroCT
quantitation of lesion volumes 21 days after injection of AAV-Cre. (Krit1fl/fl, n=4;
iPik3caH1047R, n=9; Krit1fl/fl;iPik3caH1047R, n=10). Indicated p-values are: p=0.0144;
p=0.0140; p=0.4174 (top to bottom). Data are mean ± s.e.m. Unpaired, two-tailed
Welch’s t-test. ns indicates p not significant, p>0.05; *indicates p<0.05; ***indicates
p<0.001; ****indicates p<0.0001.
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Figure 2-2.

Figure 2-1. GOF PIK3CA mutations and LOF CCM gene mutations co-exist in the
same cell in human CCMs.
a, A schematic summary of the somatic PIK3CA mutations, the germline mutations in KRIT1,
CCM2 and PDCD10, and the somatic mutations in KRIT1, CCM2 and PDCD10 as identified in
79 human CCMs via bulk sequencing of frozen resected tissue is shown. Color denotes the
affected CCM gene. Samples listed as neither familial nor sporadic are deidentified banked
CCMs lacking either clinical information or genetic evidence supporting either classification. ‡
indicates familial CCMs with an activating mutation in PIK3CA and both germline and somatic
mutations in a CCM gene. indicates known or presumed sporadic CCMs with an activating
mutation in PIK3CA and two somatic mutations in a CCM gene. b, Percentage of lesions with an
activating mutation in PIK3CA present in all sequenced CCMs vs. control brain AVMs, all three
forms of familial CCMs and sporadic CCMs. The value inside the bar shows the number of
samples in the corresponding group. c, The distributions of the 16 most common somatic PIK3CA
mutations identified in human CCMs (top) and cancer (bottom) as reported in the COSMIC
database are shown. Colored boxes represent domains in PIK3CA in order from left to right:
Adaptor BD, RAS BD, C2, Kinase. d, Schematic of workflow for processing frozen surgicallyresected human CCM lesions for single-nucleus DNA sequencing. e, Representative data for
sporadic and familial CCMs detailing the number of nuclei with each combination of PIK3CA
and CCM mutations. p was determined by two-tailed chi-squared test between the observed and
expected triple mutant nuclei predicted by a Poisson distribution (see Methods). ns indicates p not
significant, p>0.05; ***indicates p<1e-16.

!
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Figure 2-3.

Figure 2-2. Endothelial CCM LOF augments PI3K-mTORC1 signaling through
KLF4.
a, Immunostaining for phospho-S6 ribosomal protein (p-S6) and endothelial cell (EC)
marker PECAM1 in P6 hindbrain sections with a resistant (Res) or susceptible (Susc)
microbiome. White arrows indicate p-S6 positive ECs, yellow arrowheads indicate nonendothelial p-S6 positive cells in a and g. Scale bars, 50 microns. b, Immunoblot
detection of phospho-AKT (p-AKT) and p-S6 in ECs from the hindbrains of P6 control
and Krit1BECKO littermates. GAPDH loading control. c, Quantitation of immunoblotting
for p-AKT and p-S6 relative to total AKT and S6 protein. (n=8 hindbrains/group)
Indicated p-values are: p=0.0010; p=0.0003; p=0.5205 (left to right). d, Immunoblot
detection of p-AKT and p-S6 in cultured HUVECs treated with scrambled or KRIT1
siRNAs. e, Quantitation of immunoblotting for p-AKT and p-S6 relative to total AKT
and S6 protein. (n=8 individual wells/group over 4 independent experiments). Indicated
p-values are: p=0.0002; p=7e-6; p=0.1208 (left to right). f, Visual images of P6 control
and KLF4iBECGOF littermates. Images representative of 8 animals/group. Scale bars, 1mm.
g, Immunostaining for p-S6 and PECAM1 in hindbrain sections from P6 control and
KLF4iBECGOF littermates. Scale bars, 50 microns. h, Immunoblot detection of p-AKT and
p-S6 in HUVECs with expression of KLF4-GFP (“iKLF4” cells) or control lentivirus.
Tubulin loading control. i, Quantitation of immunoblotting for p-AKT and p-S6 relative
to total AKT and S6 in control and iKLF4 HUVECs. (n=6 individual wells/group over 3
independent experiments). p=0.0067; p=9e-7; p=0.0022 (left to right). j, Pathway
schematic of how gain of CCM-MEKK3-KLF2/4 signaling is proposed to augment
PI3K-mTORC1 signaling to drive CCM formation. Immunofluorescence in a and g
representative of 10 tissue sections from n=4 individual animals/genotype. Data are mean
± s.e.m. Unpaired, two-tailed Welch’s t-test. ns indicates p not significant, p>0.05;
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**indicates p<0.01; ***indicates p<0.001; ****indicates p<0.0001. For gel source data,
see Supplementary Figure 1.
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Figure 2-4.

Figure 2-3. Rapamycin prevents lesion formation due to CCM LOF and KLF4 GOF
in neonatal and adult mice.
a, Schematic of neonatal Krit1BECKO animals with a susceptible microbiome administered
a single dose treatment with Rapamycin or vehicle on P2. b, Representative visual and
microCT images of the hindbrains of littermates treated with either vehicle or
Rapamycin. Scale bars, 1mm. c, MicroCT quantitation of lesion volumes normalized to
total brain volume following treatment with vehicle or Rapamycin. (Vehicle, n=13;
Rapamycin, n=16). p=0.0009. d, Experimental design for Rapamycin or vehicle
treatment of adult animals with combined CCM LOF and PIK3CA GOF
(Krit1fl/fl;iPik3caH1047R) using cranial window surgery and AAV injection is shown. e,
Representative visual and microCT images of brains harvested 21 days after injection of
AAV-Cre into littermate animals. Dotted circles indicate the site of cranial window and
AAV-Cre injection. Scale bars, 1mm. f, MicroCT quantitation of lesion volumes 21 days
after creation of the cranial window and injection of AAV-Cre is shown. (Vehicle, n=6;
Rapamycin, n=7). p=0.0358. g, Schematic of neonatal KLF4iBECGOF animals administered
a single dose treatment with Rapamycin or vehicle followed by induction of KLF4
expression on P10. h, Representative visual and microCT images of the hindbrains of
littermates treated with either vehicle or Rapamycin. Scale bars, 1mm. i, MicroCT
quantitation of lesion volumes normalized to total brain volume following treatment of
the indicated mice with vehicle or Rapamycin. (Vehicle, n=20; Rapamycin, n=22). p=4e63
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. Data are mean ± s.e.m. Unpaired, two-tailed Welch’s t-test. *indicates p<0.05;
***indicates p<0.001; ****indicates p<0.0001.
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Extended Data Figure 2-1
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Extended Data Figure 2-1. Endothelial loss of CCM function in adult mice confers
cavernous vascular malformations in the testis but not the brain.
a, Schematic of the neonatal endothelial CCM deletion experiment. b, Cavernous
malformations form by P10 in the hindbrain of Krit1iECKO animals with a susceptible gut
microbiome. Images of hindbrains from the indicated animals are shown above, and
Hematoxylin-Eosin (H-E) stained histologic sections shown below. Arrow indicates a
CCM lesion in the white matter venous vessel. c, Schematic of CCM gene deletion in
endothelial cells (ECs) of adult mice on a susceptible microbiome background. d,
Cavernous malformations are not detected in the brain of 6 month old Krit1iECKO animals
following tamoxifen administration. Images of hindbrains from the indicated animals are
shown above, and H-E stained histologic sections shown below. e, Cavernous
malformations are detected in the testis of 6 month old Krit1iECKO animals. Images of
testis from the indicated animals are shown above and H-E stained histologic sections
shown below. * indicate blood-filled testes. Arrows indicate cavernous blood-filled
vessels around the seminiferous tubules. For panels b, d, e: Visual images representative
of n=4 animals/genotype; H-E histology representative of 6 tissue sections from n=4
animals. Scale bars for visual images, 1mm; scale bars for histology, 0.1mm. f,
Immunostaining for KLF4 and endothelial cell marker PECAM1 in brain (top) and testis
(bottom) from the experiment in c is shown. Note endothelial CCM LOF in adult mice
results in KLF4 upregulation without CCM formation in the brain. Arrows indicate
KLF4+ nuclei in PECAM1+ ECs. Yellow arrowheads indicate KLF4+ peritubular myoid
cells. Scale bars, 50 microns. g, Quantitation of KLF4+ and KLF4- ECs identified using
co-staining for KLF4 and PECAM1 in testis is shown. Quantitation from 10 individual
800micron x 800micron HPF from 3 individual animals. h, Immunostaining for
DPEAAE, a versican neo-epitope exposed by ADAMTS-mediated proteolysis, is shown
for Krit1iECKO testis. Arrows indicate peri-endothelial cell detection of DPEAAE around
testicular cavernomas. Scale bars, 0.1mm. “Control” genotype in panels b, d, e, f, g
indicate animals with genotypes of either Cdh5-CreERT2; Krit1fl/+ or Krit1fl/fl.
Immunofluorescence images in f & h representative of 6 tissue sections from n=4
individual animals/genotype.
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Extended Data Figure 2-2

Extended Data Figure 2-2. Vascular lesions due to CCM LOF and/or PIK3CA GOF
arise in veins of the white matter.
a, Schematic of neonatal endothelial induction of Krit1 deletion and/or PIK3CAH1047R
expression. b & c, Hematoxylin-Eosin (H-E) staining of saggital hindbrain sections from
P6 control, Pik3caiBECGOF, Krit1iBECKO;Pik3caiBECGOF (b and b’) and Krit1iBECKO (c and
c’) animals with a resistant (Res) or susceptible (Susc) microbiome. b’and c’ samples
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were obtained from animals distinct from those in b and c. Note that lesions form in the
white matter with both CCM loss of function and PIK3CA gain of function. Boxes in
upper images denote area of magnified image immediately below. Dotted lines outline
the white matter of the cerebellum. Arrows indicate lesions in white matter veins and
venules. H-E images representative of 6 tissue sections from n=4 animals/genotype. wm,
white matter. Scale bars, 0.1mm.
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Extended Data Figure 2-3

Extended Data Figure 2-3. Endothelial Pten LOF synergizes with Krit1 LOF in a
dose-dependent manner.
a, Schematic of neonatal endothelial induction with tamoxifen of Krit1 deletion and
deletion of either none or one allele of Pten in endothelial cells using a Pdgfb-CreERT2
transgene. b, Representative visual and paired microCT images of Krit1iECKO and
Krit1iECKO;Ptenfl/+ littermate mice on a susceptible microbiome background at P12. Scale
bars, 1mm. These mice were produced from a Ptenfl/+ x Ptenfl/+ cross; however no
Krit1iECKO;Ptenfl/fl littermates survived to P12. c, MicroCT quantification of lesion
volumes at P12. (Krit1iECKO, n=6; Krit1iECKO;Ptenfl/+, n=13). d, Schematic of neonatal
endothelial induction of Krit1 deletion and deletion of either one or both alleles of Pten in
endothelial cells using a Pdgfb-CreERT2 transgene with brains harvested at P7. These
mice were produced from a Ptenfl/+ x Ptenfl/fl cross. e, Representative visual and paired
microCT images in Krit1iECKO;Ptenfl/+ and Krit1iECKO;PteniECKO littermate mice at P7.
Scale bars, 1mm. f, MicroCT quantification of lesion volumes at P7. (Krit1iECKO;Ptenfl/+,
n=13; Krit1iECKO;PteniECKO, n=8). Data are mean ± s.e.m. Unpaired, two-tailed Welch’s ttest.
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Extended Data Figure 2-4

Extended Data Figure 2-4. Uninduced Slco1c1-CreERT2; Krit1fl/fl; iPik3caH1047R
animals develop focal lesions due to Slco1c1-CreERT2 transgene endothelial leak.
a, Schematic for generation of a survival curve in the absence of tamoxifen
administration. b, Postnatal survival curve in the absence of tamoxifen administration is
shown for indicated genotypes. (Slco1c1-CreERT2;Krit1fl/fl, n=15, Slco1c1CreERT2;Krit1fl/+;iPik3caH1047R n=10, Slco1c1-CreERT2;Krit1fl/fl;iPik3caH1047R n=39).
Log-rank test. c, Representative visual and paired microCT images of brains harvested
from untreated P28 littermates. Scale bars, 1mm. d, MicroCT quantitation of lesion
volumes of untreated P28 animals. (Slco1c1-CreERT2;Krit1fl/fl, n=5, Slco1c1CreERT2;Krit1fl/+;iPik3caH1047R n=9, Slco1c1-CreERT2;Krit1fl/fl;iPik3caH1047R n=10).
Data are mean ± s.e.m. Unpaired, two-tailed Welch’s t-test. e, Additional visual images
of brains from a superior and inferior perspective from animals harvested at various
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timepoints (P19-P36). Arrows point to focal vascular lesions. Scale bars, 1mm. f, Leak
assessed by immunostaining of brain sections with antibodies against GFP to identify
Cre-expressing cells, and cell surface marker PECAM1 (top) and nuclear protein ERG
(bottom) to identify endothelial cells is shown. Scale bars, 50 microns.
Immunofluorescence images representative of 10 tissue sections from n=4 individual
animals/genotype. g, Quantitation of GFP+; ERG+ nuclei (n = 242) and GFP+; ERGnuclei (n = 3) from 20 individual 800micron x 800micron HPF.
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Extended Data Figure 2-5

Extended Data Figure 2-5. Exogenous delivery of Cre recombinase via AAV vector
to drive combined loss of CCM function and gain of PIK3CA function results in
CCM formation in the adult brain.
a, A schematic of the experimental approach in which a cranial window is created and
AAV-Cre virus injected into the brains of 2 month old mice with serial imaging at postoperative days 1, 7, 10, 14, 18, and 21. b, Representative visual images of brains
harvested 21 days after injection of AAV-Cre into adult animals. Dotted circles indicate
the site of cranial window and AAV-Cre injection. Includes visual images displayed in
Figure 1. Scale bars, 1mm. c, Serial images obtained through the same cranial window of
mice of indicated genotypes following injection of AAV-Cre. iPik3caH1047R designation
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includes iPik3caH1047R and/or Krit1fl/+;iPik3caH1047R genotypes. White arrows indicate
cavernous malformations in Krit1fl/fl;iPik3caH1047R mice. Black arrows indicate
hypervascularity in iPik3caH1047R mice. d, Peri-lesional iron deposition stain in brains
indicative of chronic bleed from four independent Krit1fl/fl;iPik3caH1047R mice at post-op
day 21. Scale bars, 200 microns.
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Extended Data Figure 2-6

Extended Data Figure 2-6. Lineage tracing of AAV-Cre activity after direct
injection into the mouse brain.
AAV-Cre virus was injected into the brain of Ai14 Cre reporter animals and Cre activity
assessed by detection of the tdTomato (RFP) reporter 14 days after injection. a-c,
Confocal microscopic overview from a, the injection site; b, the border region of the viral
spread and c, the contralateral cortex of AAV-Cre injected Ai14 mice two weeks after
stereotactic injection. AAV-Cre transduced cells expressed red fluorescent protein (RFP)
(shown in white). RFP-positive vessels were identified by colocalization with PECAM1
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(shown in red). White arrows point to representative RFP-positive vessels. Yellow
arrowheads point to RFP-expressing neuronal cells. Scale bar, 100 microns. Boxed
regions in 1 and 2 are shown at higher magnification on the right. 1 & 2 show PECAM1
staining for endothelial cells overlaid with RFP signal; 1’ & 2’ show PECAM staining
alone; 1” & 2” shown RFP staining alone. These data are representative 12 separate
images from 8 tissue sections from n=2 individual animals. Scale bar, 20 microns.
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Extended Data Figure 2-7

Extended Data Figure 2-7. Characterization of single-nucleus DNA sequencing of
human CCM samples.
a, The relationship between somatic PIK3CA and CCM mutations detected in bulk
sequencing is graphed. Points indicate individual mutations in either a CCM gene or
PIK3CA. Lines connect the CCM gene and PIK3CA gene mutations present in a single
sample. Box plots show the aggregate frequencies of PIK3CA and CCM mutations.
Center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers
extend 1.5 times the interquartile range from the 25th to 75th percentiles, outliers are
represented by dots. n = 21 sample points for both plots. b, Representative FANS plots of
unstained (top row) and DAPI stained (bottom row) CCM homogenate. Doublet
discrimination by forward scatter profile for DAPI stained sample. Plots consist of
100,000 events. The unstained sample contains 1 event (0%) in the DAPI+ singlet gate.
The DAPI stained samples contains 2,414 events (2.4%) in the DAPI+ singlet gate. c,
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Total reads and average coverage per nucleus from snDNAseq for each mutation detected
by bulk sequencing. Dotted line shows 20x coverage, the minimum cutoff used for
establishing genotype. d, Pseudobulk allele frequency from snDNA-seq for each
mutation detected by bulk sequencing. Dotted line shows 1% allele frequency. Note the
data point with the arrow in c-d shows a mutation in sample 5079 detected in bulk
sequencing which, due to poor amplification during snDNA-seq, received insufficient
coverage per nucleus (4.5x) to establish nuclear genotypes however is clearly present in
pseudobulk reads (1849/9814). e, Comparison of mutation allele frequency as detected by
bulk and snDNA-seq. As nuclei are diploid for the relevant autosomes, the x-axis is equal
to the fraction of mutant nuclei divided by two. Dotted line shows perfect correlation at
x=y. R and p were calculated by Pearson’s correlation coefficient. f, A summary of
snDNA-seq results for 3 sporadic and 2 familial CCMs analyzed is shown. The number
of nuclei with each possible genotype are listed. + indicates a wild-type allele; * indicates
a mutant allele. Note that only 1 somatic CCM mutation was identified in samples 5038
and 5079. P values were determined by two-tailed chi-squared test between the observed
and expected triple mutant nuclei (or double mutant for lesions 5038 and 5079)
determined by Poisson distribution (see Methods).
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Extended Data Figure 2-8

Extended Data Figure 2-8. PI3K signaling does not augment MEKK3-KLF2/4
signaling.
a, Diagram of how gain of PI3K signaling might augment CCM formation by acting
upstream of MEKK3-KLF2/4 signaling in endothelial cells. b, Immunostaining for KLF4
and the endothelial cell marker PECAM1 in hindbrain sections from P6 control,
Krit1BECKO, Pik3caiBECGOF, and Krit1iBECKO;Pik3caiBECGOF neonates with either a
susceptible (Susc) or resistant (Res) gut microbiome is shown. White arrows indicate
endothelial cell nuclear KLF4 staining. Immunofluorescence images representative of 10
tissue sections from n=4 individual animals/genotype. Control animals are either
Slco1c1-Cre;Krit1fl/+ or Krit1fl/fl. Scale bars, 50 microns. c, Measurement of Klf2 and Klf4
mRNA in endothelial cells isolated from the hindbrains of P6 control, Krit1BECKO and
Pik3caiBECGOF neonates. (Control, n=8; Krit1BECKO, n=6; Pik3caiBECGOF, n=8). d,
Measurement of KLF2 and KLF4 mRNA in human umbilical vein endothelial cells
(HUVECs) treated with the indicated siRNAs or lentiviral vectors. (n=6 individual
wells/group over 2 independent experiments). Data are mean ± s.e.m. Unpaired, twotailed Welch’s t-test.
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Extended Data Figure 2-9

Extended Data Figure 2-9. The CCM effector KLF4 augments endothelial cell
PI3K-mTORC1 signaling.
a, Schematic of neonatal endothelial induction of KLF4 expression in KLF4iBECGOF
animals. b, Immunostaining for KLF4 and the endothelial cell marker PECAM1 in
hindbrain sections from P6 control and KLF4iBECGOF animals is shown. Boxes in upper
images denote area of magnified image immediately below. Immunofluorescence images
representative of 6 tissue sections from n=4 individual animals/genotype. Scale bars, 50
microns. c, H-E stained sections of hindbrain from control and KLF4iBECGOF littermates.
Boxes in upper images denote area of magnified image immediately below. Black arrows
indicate lesions. Dotted lines outline the white matter of the cerebellum. wm, white
matter. Note the dilated white matter venules similar to those observed with CCM loss of
function and PIK3CA gain of function shown in Extended Data Figure 2. H-E histology
representative of 6 tissue sections from n=4 animals/genotype. Scale bars, 0.1mm. d,
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Immunostaining for phospho-S6 ribosomal protein (p-S6) and the endothelial cell marker
PECAM1 in hindbrain sections from P6 control and KLF4iBECGOF animals is shown.
White arrows indicate p-S6 positive endothelial cells. Yellow arrowheads into nonendothelial p-S6 positive cells. Immunofluorescence images representative of 6 tissue
sections from n=4 individual animals/genotype. Scale bars, 50 microns. e, Immunoblot
detection of KLF4, KLF4-GFP, the KLF4 target gene eNOS in HUVECs without and
with inducible lentiviral expression of KLF4-GFP (“iKLF4” cells) or control lentivirus.
TUBULIN is shown as a loading control.
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Extended Data Figure 2-10

Extended Data Figure 2-10. Rapamycin rescue of CCM formation is independent of
KLF4.
a, A schematic of the experimental approach in which a cranial window is created and
AAV-Cre virus injected into the brains of 2 month old mice and along with daily
injection of vehicle, 100ug of Rapamycin (Rapa-low), or 400ug of Rapamycin (Rapahigh) started at post-op day 7 continuing through post-op day 21 with serial imaging at
post-op day 1, 7, 10, 14, 18, and 21. b, Representative visual images of brains harvested
21 days after injection of AAV-Cre and 2 weeks of daily vehicle or rapamycin (low
dose/high dose) treatment in Krit1fl/fl;iPik3caH1047R mice. Dotted circles indicate the site
of cranial window and AAV-Cre injection. Arrows indicate detached lesions. Scale bars,
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1mm. c, Serial images obtained through the same cranial window of
Krit1fl/fl;iPik3caH1047R mice following injection of AAV-Cre and subsequent treatment.
Arrows indicate formation and growth of individual cavernous malformations. d,
MicroCT quantitation of lesion volumes 21 days after creation of the cranial window and
injection of AAV-Cre. Values include duplication of microCT values in Figure 4 (vehicle
and low dose treatments). (Vehicle, n=6; Rapa-low, n=7; Rapa-high, n=7). Data are mean
± s.e.m. Unpaired, two-tailed Welch’s t-test. e, Schematic of neonatal endothelial
induction of Krit1 deletion and treatment with Rapamyin or vehicle control at P2. f,
Immunostaining of hindbrain sections from P6 Krit1iBECKO animals treated with vehicle
or Rapamycin for PECAM1 and p-S6. White arrows indicate p-S6 positive endothelial
cells in the control but not the Rapmycin treated animal. Yellow arrowheads indicate pS6 positive neuronal cells. g, Immunostaining of hindbrain sections from P6 Krit1iBECKO
animals treated with vehicle or Rapamycin for PECAM1 and KLF4. White arrows
indicate KLF4-positive endothelial cells detected in the control and in the Rapmycin
treated animal. Scale bars, 50 microns.
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CHAPTER 3: Adamts5 Proteases and Cardiac Biology
3.1 Author’s note
This chapter is on a project that I started when I first joined the lab. Most of this
work was done during the first half of 2018 for my PhD qualifying exam, which was
ultimately unrelated to my thesis project. It consists of unfinished and unpublished work
that will be a stand-alone chapter and unconnected to the remainder of this dissertation.
3.2 Introduction to Cardiovascular Extracellular Matrix
The cardiovascular extracellular matrix (ECM) is a complex and dynamic entity
that plays a crucial, but often overlooked, role in cardiovascular physiology and pathology.
The role of the ECM has evolved in the minds of scientists from a passive mesh that hold
cells together, to what we now know is a functional network that provides signals and
transmits force to the cells that it connects139-141. In the heart, the organ that sees the highest
intravascular pressures in the body, ECM is highly responsive to mechanical loading and
plays a central role in the physiologic and pathologic remodeling that occurs in response
to changes in mechanical stress142-145. This complex remodeling process involves both
production and degradation of matrix, mediated by secretion of proteins and proteases from
surrounding cells to alter the organization of ECM145. In addition to normal physiology,
tight spatial-temporal and compositional regulation of the ECM in the heart and vasculature
is necessary for proper embryogenesis146-150.
During embryonic development, provisional matrix consisting of soft, hydrated
proteoglycans is replaced with more organized, fibrous proteins150. Cardiac jelly is one
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such provisional matrix, found between the endocardium and myocardium, and consists
primarily of the proteoglycan versican146. The previously identified versican functional
null heart defect (vcanhdf/hdf) mouse model is embryonic lethal at 10.5 days of gestation
(E10.5) due to a lack of cardiac jelly and its resulting severe heart defects151-153. Thorough
descriptive studies have shown that versican is imperative for cardiac cushion formation
and ultimately responsible for secondary heart field structures including proper
atrioventricular valve formation, chamber septation, and outflow tract development151.
However, there has not been a characterized mechanism by which versican and cardiac
jelly confers its effects on the developing heart. In the heart as in other tissues, versican
expression is highest during the embryonic stages and is much reduced in adult tissues154.
Cardiac versican levels decline significantly in the post-natal animal150,155, but we observe
the residual versican localized to specific regions of the neonatal and mature mouse heart.
Due to the embryonic lethality of the versican null mouse and the lack of genetic mouse
models, most of the studies on versican have been largely descriptive or under in vitro
conditions. It is unclear what in vivo function, if any, versican has in the post-natal heart.
In the cardiovascular system, the extracellular matrix imparts many unique
biophysical properties that permit a dynamic system to function under repetitive stress,
providing tensile strength and structural scaffolding as well as the ability to distend to
accommodate changes in volume and pressure146,156. Disruption of ECM remodeling and
mechanical homeostasis can lead to cardiovascular disease143,144,157. However, we still lack
understanding of how the specific composition and regulation of the ECM confer these
physiological effects. Collectively, these form the foundation of my hypothesis that
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versican plays a role in regulating the biophysical properties of the dynamic cardiovascular
structures.
3.3 Versican and ADAMTS proteases
Versican is a member of the hyalectan protein family of proteoglycans, as defined
by their ability to bind hyaluronan158-160. Unlike the other hyalectans including aggrecan161,
brevican162, and neurocan163, versican has a broad tissue distribution and is expressed in
the developing heart and limb, vascular smooth muscle cells, and fibroblasts149,155,164,165.
Versican is produced as multiple alternatively spliced isoforms which share conserved core
protein motifs, containing homologous N-terminal and C-terminal domains, but differ in
their glycosaminoglycan (GAG) attachment domains164. The N-terminal G1 globular
domain binds to hyaluronan and the two GAG domains, GAG-a and GAG-b, classify
versican as a chondroitin sulfate (CS) proteoglycan, containing CS GAGs that impart a
strong negative charge and permit hydration that give versican its compression-resistant
properties160. These modular structures serve to bind matrix components such as collagen,
fibrillin, and fibulin,

166,167

as well as cellular components such as integrin168, allowing

versican to participate in biological functions through ECM-ECM and ECM-cell
interactions.
The main method by which versican and other hyalectans are regulated is through
proteolytic modification by the “a disintegrin and metalloproteinase with thrombospondin
motifs” (ADAMTS) family of secreted matrix metalloproteases169,170. Multiple ADAMTS
proteases, including ADAMTS1, 4, 5, 9, 15, and 20 cleave versican171-173. These ADAMTS
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proteases are highly homologous and share redundant functions in hyalectan proteolysis174176

. Predictably, both versican and its ADAMTS proteases are often expressed concurrently

in tissues171, such as during heart development, and only collectively do they allow for
remodeling that is necessary for proper heart development as described above155,171,177,178.
The primary versican cleavage site lies within the GAG-b domain, leading to the
production of a 70kDA fragment and a resulting neoepitope at the G1-DPEAAE (DP)
peptide motif that can be detected by antibodies172. It is known that there exists at least one
other cleavage site within the GAG-a domain179.
3.4 Results: Versican in the post-natal heart
Alan Tang, a member of the Kahn lab, designed and generated an extensive toolbox
of transgenic mouse lines in the lab that enabled us to begin these investigations. The first
of many mice was the Versican-CreERT2-tdTomato mouse which was a knock-in system
that labeled all versican producing cells with an RFP and provided an inducible cre system.
Initial characterization of this mouse was via a simple lineage trace of the allele in the heart
using am RFP cre reporter. We observed punctate reporter signal in a thin layer of the
endocardium lining the inside of both ventricles (Figure 3-1).
Where is versican located in the post-natal heart? Using versican antibody staining
on wildtype hearts, we observed that versican was located primarily around the bicuspid
and tricuspid valves of the heart (Figure 3-7) with some additional staining along the
outflow tract. This was unexpected because we did not observe any versican in the
endocardium or myocardium of the heart outside of the staining in the valves, including
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around the RFP labeled cells in the endocardium. What are these versican-producing cells
and what is their role?
This observation suggested to us that there may be a novel, non-developmental,
function for versican in the heart that has yet to be understood. Due to the embryonic
lethality of the versican null mouse and the lack of genetic mouse models, most of the
studies on versican have been largely descriptive.
3.5 Results: ADAMTS5 Global Overexpression
Another mouse designed in our lab was the tetracycline-on (tet-O) ADAMTS5
gain-of-function (GOF) mouse. Adamts5 is one of the major versican proteases and more
enzymatically active than its respective versicanase counterparts180. This system combines
a reverse tetracycline transactivator (rtTA) with a tetracycline-responsive promoter,
allowing for quantitatively and temporally controlled over-expression of the downstream
target transgene upon administration of doxycycline, in this case Adamts5. When
combined with a global Rosa26-CAG-rtTA2+/0, this system globally overexpresses
ADAMTS5. When administered doxycycline in neonatal mice on the 6th day of life (P6),
these ADAMTS5 GOF mice of genotype Rosa26-CAG-rtTA2+/0, tetO-adamts5L2+/0 die
within 24 hours of retroorbital injection with doxycycline. Post-mortem analysis showed
gross morphological changes of the heart and dramatic deformation of cardiac architecture.
(Figure 2a)
Histologic analysis of the mouse showed severe changes in the gross morphology
of the heart, including deformation of the ventricular walls that resemble cardiac
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hypertrophy. We confirmed expression of ADAMTS5 using a V5 tag and observed a
corresponding increase in versican DP cleavage products by immunohistochemistry
(Figure 2b). This phenotype was entirely unexpected because ADAMTS5 is thought to
cleave specifically versican, and versican has never been shown to have a role in the postnatal heart. It is possible that the enormous levels of ADAMTS5 overexpression could lead
to non-specific cleavage of other proteoglycans.
The next step was to evaluate the phenotype’s persistence in the adult animal. I was
surprised to see that the phenotype was indeed maintained. The adult animals also rapidly
became sick and died. I observed the ADAMTS5 heart was much smaller than the control
animal heart upon harvest. To further characterize cardiac function of these animals while
still alive, echocardiography was performed on these mice. On echo, the small chambers
of the ventricle during systole and diastole coupled with thickened walls suggested to us a
pseudohypertrophy

phenotype

(Figure

3a).

The

calculated

echocardiographic

measurements showed an increased ejection fraction and increased fractional shortening
which was consistent with a hypertrophic phenotype (Figure 3b). Calculations also
confirmed decreased LV mass which was consistent with the observation of the “shrunken”
heart being smaller than its control counterpart.
Our initial hypothesis was that this phenotype is the result of versican cleavage by
ADAMTS5 in the heart and suggests an imperative role of versican in maintenance of
cardiac architecture in the post-natal animal. Unfortunately, further analysis revealed that
this seemingly dramatic phenotype was in fact, a simple artifact all along. Importantly, I
observed a GI bleed in my doxycycline-induced animals. There was dark blood throughout
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the intestine and colon in the abdomen of the mouse, but I did not think it was the primary
cause of the cardiac phenotype. However, after perfusion and fixation of the heart, the
phenotype disappeared (Figure 4). What does this imply? Restoration of volume to the
heart during the intra-cardiac perfusion process (10ml PBS + 10ml 4% PFA) was able to
correct the apparent cardiac morphologic defect. This suggests that loss of preload led to
the apparent collapse of the heart and is consistent with hypovolemic shock, likely
secondary to GI bleed. As a result, no major conclusions could be drawn from this
experiment. It is unclear what the ADAMTS5 was doing in the gut to cause the bleed, but
the question is largely irrelevant and difficult to test.
3.6 Results: ADAMTS5 Cardiac Overexpression
Prior to the realization that the global ADAMTS5 experiment heart phenotype was
an artifact due to hypovolemia, we inferred a cardiac function for versican in the post-natal
animal. As a result, I had already begun the breeding of an experiment to test whether this
phenotype was the result of a heart-intrinsic mechanism using tissue-specific
overexpression of ADAMTS5. It was logical to perform the experiment regardless of the
global phenotype. The genetic set up was as follows: the constitutive cardiac troponin T
cre (cTNT-cre) would drive expression of the cre-dependent rtTA (LSL-rtTA). Then upon
administration of doxycycline, all cells with cre-driven expression of rtTA, in this case
predominantly cardiomyocytes would activate the Adamts5 transgene.
What we observed was not a recapitulation of the initial phenotype, but something
just as striking. In the neonatal animals, the doxycycline induced animals died after a few
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days, similar to the global overexpression. When harvested 24 hours after induction at P7,
we did not see any GI bleed, but we observed that the heart appeared to be more spherical
in shape, rather than maintaining a standard apical morphology. In these animals, we preemptively perfused the hearts to prevent a similar artifactual finding as before. Histological
examination showed disintegration of the ventricular wall, what appeared to be separation
of the muscle layers, and overall loss of apical architecture. (Figure 5)
I decided to repeat this experiment in the adult animal and observed the same
phenotype as in the neonate. Even just 48 hours after induction, the adult ADAMTS5 GOF
heart also lost its standard shape and became elongated, even beyond spherical, to a
“football-like” shape immediate apparent upon opening the thoracic cavity (Figure 6a).
These animals were then characterized by functional evaluation of cardiac function using
echocardiographic studies. Echocardiography revealed that these animals showed a barrelshaped cavity, with an endocardial ventricular wall that was separating from the rest of the
cardiac myocytes, seemingly a type of non-compaction phenotype. Both in long axis and
short axis views of the ventricular chamber, we observed “holes” in the myocardium that
we decided to term “pseudo-trabeculation” (Figure 6b), to distinguish it from the
physiological trabeculation that occurs during development. At first glance, this phenotype
did in fact resemble the embryonic cardiac trabeculation process. Histologic analysis
confirmed this observation, showing an overall rounded shape of the heart, loss of apical
architecture, and multiple pockets in the endocardial wall rather than a smooth ventricular
lining (Figure 7a).
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Immunohistochemistry offered some more insight into this bizarre phenotype.
These pseudo-trabeculae additionally stain positive for versican, which was an unexpected
finding (Figure7b). Where does all this versican come from when there is no versican
staining to be found in the control ventricular wall? When stained with PECAM1, an
endothelial marker, we observed that these pseudo-trabeculae were endothelial lined
(Figure 8). This suggested that it wasn’t purely a mechanical process of non-compaction,
otherwise proteolytic shredding of the myocardium would not result in endothelial lined
walls. Staining for DPEAAE versican cleavage product confirmed that versican was
cleaved in these hearts (Figure 8). In addition, Ki-67 staining suggests that proliferation is
at least partially responsible for the increased endothelial surface area (Figure 8). It is
unclear from 2D histologic analysis how deep these fissures are. Our hypothesis has been
amended to the thought that versican is present throughout the endocardium of the postnatal animal, but the epitopes that the antibody recognizes is hidden by protein
modifications and the compact structural matrix of the heart. Upon ADAMTS5 cleavage,
these epitopes are exposed and the anti-versican antibody can recognize it for
immunohistochemistry. Likely, there is a network of versican fibers just underneath the
endocardial layer (Figure 8) that is only apparent after proteolytic activity.
This cardiac phenotype is the direct result of ADAMTS5 overexpression in the
heart. Given the specificity of ADAMTS5 in cleaving versican, the phenotype suggests an
imperative and previously unidentified role of versican in maintenance of cardiac
architecture in the post-natal animal. Ideally, the next question was to test whether this
phenotype was versican dependent. The plan was to use a lab-designed versican mutant
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mice that had mutations in the primary cleavage site that would prevent cleavage by
ADAMTS5. If this phenotype were truly versican-dependent, a mutant uncleavable
versican would rescue the phenotype and therefore show that versican is the relevant
substrate. However, characterization of the versican mutant by another graduate student
revealed that these uncleavable mutant mice had no phenotype and was still getting cleaved
by proteases, potentially at an alternative cleavage site.
Unfortunately, following several preliminary experiments, the lab had difficulties
in the mouse facility with breeding. For unrelated reasons, the litter sizes were small
because of mouse facility conditions. Coupled with a 1:8 or 1:4 breeding scheme, there
were very few experimental pups able to be analyzed. It is also possible that a small amount
of leak or toxicity of the transgene that probably resulted in the early lethality of the pups.
At this point in mid 2018, my main thesis work had taken off and I tabled this project to
focus on the CCM project.
3.7 Summary and Future Directions
Versican is a proteoglycan that has been characterized as a critical mediator of
embryonic heart development but has never been shown to have a function in the postnatal heart. Limitations of in vitro systems for study of extracellular matrix proteins as well
as a lack of suitable in vivo models have been an obstacle to studying versican in
physiologically meaningful manner. Despite the impact versican has on various
physiological processes, the underlying mechanisms are largely unknown. We stand to
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learn much about both versican biology and how this ECM protein provides a dynamic
way of altering cardiovascular physiology.
These experiments are only the first steps towards elucidating the function of
versican in the post-natal heart. Remaining questions are numerous and will undoubtedly
be a challenge to tackle. Extracellular matrix proteins present a challenge at baseline and
with versican, it is likely that the protein’s function is more than just its biophysical
properties. Evidence from our lab and others suggests that the cleavage process itself
releases bioactive fragments that act on neighboring cells in a cell non-autonomous
fashion47,155. Whether the versican cleavage fragments themselves (i.e., versikine and the
like) or growth factors released upon proteolytic cleavage are responsible for signaling are
still unknown.
Even in my short period working on this project, I encountered the obstacle of
utilizing an artificial system to shed light on normal physiology. Evaluators during my
preliminary exam remarked on the lack of a clear question and translational application of
the model system. The ADAMTS5 GOF mouse, because it is a gain of function system,
does not model, and is not supposed model, a normal physiologic process. Rather, this
mouse is a tool for testing a specific question regarding versican cleavage. However, the
hope is that this “Frankenstein” mouse will help reveal a role for versican that was not
previously described, to be followed up with other genetic models in the lab. The genetic
toolkit in the lab is well equipped but it will take a keen eye and a determined mind to
tackle this project.
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3.8 Methods
Mice
cTNT-cre (JAX catalogue number 024240) and Cag-rtTA3 (JAX catalogue number
016532) mice were purchased from JAX. R26–CAGs–LSL–rtTA3 mice (JAX catalogue
number 029617) were provided by Lukas Dow. Versican-tdTomato-creERT2 and TetOAdamts5 mice were generated and validated in the lab. All experimental animals were
maintained on a mixed-strain background, and littermate controls were used for neonatal
experiments unless otherwise indicated. Breeding pairs between two and eight months of
age were used to generate mice of the indicated genotypes. Sample size was determined
from prior studies using similar animals and techniques.
Doxycycline induction for TetO-ADAMTS5 mice
Fresh aliquot of doxycycline (Sigma D9891) made immediately before injection. 10mg/ml
aliquot resuspended in sterile PBS.
Neonate doxycycline injection: Pups were injected at P6 intraperitoneally with 500ug of
the doxycycline solution (50ul) or 300ug injected retroorbital. Hearts were harvested at P7,
24 hours after dox administration.
Adult doxycycline injection: All experimental mice were at least 3 months of age. On day
0 and 1, mice were given 1mg doxycycline (100ul) via oral gavage. 48 hours after initial
gavage, mice were evaluated by echocardiography and harvested.
Echocardiography
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All echocardiography was performed by the Penn Cardiovascular Institute Mouse
Cardiovascular Phenotyping Core. Echocardiography was performed by a trained
technician to determine end systolic and end diastolic volumes of the left ventricle.
Ultrasound examination of the left ventricle was performed using a Fujifilm VisualSonics
Ultrasound System (VisualSonics Inc, Toronto, ON, Canada) and using MS400 (18-38
MHZ) transducer. Mice were lightly anesthetized with an i.p. injection of 0.005 ml/g of
2% Avertin (2,2,2-Tribromoethanol, Sigma-Aldrich, St. Louis, MO). Hair was removed
from the anterior chest using chemical hair remover (Nair), and the animals were placed
on a warming pad in a left lateral decubitus position to maintain normothermia (37°C),
monitored by a rectal thermometer. Ultrasound gel was applied to the chest. Care was taken
to maintain adequate contact while avoiding excessive pressure on the chest. Left
ventricular (LV) systolic function: Two-dimensional long-axis, short-axis M-Mode images
were obtained. After completion of the imaging studies, mice were allowed to recover from
anesthesia and returned to their cages. 20D Long Axis images were analyzed for Heart rate,
end diastolic volume, end systolic volume and ejection fraction using Vevo Lab software
(Visual Sonics Inc, Toronto, ON, Canada).
Histology and immunohistochemistry
Mice were anaesthetized with an intraperitoneal injection of tribromoethanol (Avertin),
followed by intracardial perfusion with 20 ml of cold PBS and 4% (w/v) paraformaldehyde
(PFA) in PBS (pH 7.4) for adult mice and 10 ml respectively for neonates. Tissue samples
were fixed in 4% PFA/PBS overnight at 4 °C, dehydrated to 100% ethanol, and embedded
in paraffin. Tissue sections of 6 μm underwent dewaxing and rehydration through xylene
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and ethanol treatment, and were subsequently used for haematoxylin-and-eosin and
immunohistochemistry staining. For immunodetection, 10 mM citrate buffer (pH 6)
(Sigma, catalogue number C9999) was used for antigen retrieval, and sections were
blocked with 10% donkey serum in 1% bovine serum albumin (BSA) before primary
antibody treatment overnight at 4 °C.
The following primary antibodies were used for immunostaining: anti-versican (Abcam
#ab177480), anti-versican DPEAAE neoepitope (Invitrogen #PA1-1748A), anti-V5 (Cell
Signaling Technology #13202), anti-RFP (Abcam #ab62341) that have previously been
validated for use in paraffin-embedded immunostaining. Fluorescence-conjugated Alexa
Fluor secondary antibodies were used (1:500, Invitrogen) according to the primary
antibody species and counterstained with DAPI (1:1,000). Secondary antibodies were
validated for nonspecific staining by no primary antibody negative controls.
Control and experimental animal sections were stained at the same time under identical
conditions. Sections were mounted on slides with ProLong Gold Antifade reagent. Images
were acquired on a Nikon 80i Eclipse, an Olympus DP80 microscope, and/or a Zeiss LSM
710 or Zeiss 880 confocal microscope at the same exposure times, using ×4, ×10, ×20 and
×40 objectives, and subsequently processed in ImageJ software (National Institutes of
Health, NIH).
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3.9 Figures
Figure 3-1.

Figure 3-1. RFP expression from versican producing cells in the heart is limited to
the endocardial surface.
Immunostaining for RFP and DAPI in hearts isolated from P10 littermates in control
(top) and Vcan-tdTomato-creERT2; Ai14 mice (bottom). LV = left ventricle, Ao = Aorta,
S = septum.
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Figure 3-2.
A.

B.

Figure 3-2. Cardiac morphological change and increased versican cleavage product
in the heart of mice with global expression of ADAMTS5.
A. Hematoxylin-Eosin (H-E) stained histologic sections from hearts isolated from P7
littermates of control (left) and global tetO-Adamts5 (right) animals. Hearts harvested
without perfusion and fixation. B. Immunostaining for DPEAAE, a versican neo-epitope
exposed by ADAMTS-mediated proteolysis and DAPI in P7 littermates of control and
ADAMTS5 GOF animals.
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Figure 3-3.
A.

B.

Figure 3-3. Echocardiographic analysis of adult global TetO-ADAMTS5 mice show
thickened walls and small ventricular chamber.
A. Echocardiography performed on littermate adult animals. Short axis view of left
ventricle shown. Dotted red concentric circles indicate the inner and outer borders of the
ventricular wall. B. Calculated ejection fraction and fractional shortening is increased in
the treatment group and left ventricular mass is decreased in the doxycycline treated
group.
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Figure 3-4.

Figure 3-4. Perfusion of global ADAMTS5 GOF heart rescues altered cardiac
morphology.
Hematoxylin-Eosin (H-E) stained histologic sections from hearts isolated from adult
littermates of control (left) and global tetO-Adamts5 (right) animals. Hearts harvested
after intracardiac perfusion and fixation with 10ml of PBS and 10ml of 4% PFA in PBS.

Figure 3-5.

Figure 3-5. Neonatal cardiac specific overexpression of ADAMTS5 results in severe
deformation of the ventricular wall.
Hematoxylin-Eosin (H-E) stained histologic sections from hearts isolated from neonatal
P7 littermates of control (left) and cTNT driven tetO-Adamts5 (right) animals. Hearts
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harvested after intracardiac perfusion and fixation with 5ml of PBS and 5ml of 4% PFA
in PBS.

Figure 3-6.
A.

B.
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Figure 3-6. Adult cardiac specific overexpression of ADAMTS5 results in severe
deformation of cardiac morphology.
A. Gross image of heart in thorax of adult cTNT driven tetO-Adamts5 animals. Note the
loss of apical architecture. B. Echocardiographic images shown in long-axis (top) and
short-axis (bottom) views of the cardiac ADAMTS5 GOF heart. Arrows point to
separation of the ventricular wall including scalloped inner surface and formation of
“false” chambers.
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Figure 3-7.
A.

B.

Figure 3-7. Cardiac specific overexpression of ADAMTS5 results in severe
deformation of the ventricular wall.
A, Hematoxylin-Eosin (H-E) stained histologic sections from hearts isolated from adult
littermates of control (left) and cTNT driven tetO-Adamts5 (right) animals. Hearts
harvested after intracardiac perfusion and fixation with 10ml of PBS and 10ml of 4%
PFA in PBS. B, Versican staining reveals large amounts of versican lining the pseudotrabeculae. Blue and pink borders indicate regions shown at a higher magnification
(bottom).
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Figure 3-8.

Figure 3-8. Pseudo-trabeculae in cardiac specific overexpression of ADAMTS5 is
lined with proliferative endothelium and versican.
Immunostained histologic sections from hearts isolated from adult cTNT driven tetOAdamts5 (right) animals. Hearts harvested after intracardiac perfusion and fixation with
10ml of PBS and 10ml of 4% PFA in PBS.
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CHAPTER 4: General Conclusions and Future Directions
4.1 General Summary
This work is the culmination of many years of CCM research in the Kahn lab and
other research labs in the field. The molecular and genetic foundations of this disease made
over the past two decades have provided the framework upon which I built this work. This
work answers a key question in the pathogenesis of CCM disease and offers insight into
the growth of vascular malformations.
The question began with a fact widely known, yet often swept under the rug by the
CCM field. The neonatal CCM mouse model relies on early deletion of the CCM genes
and outside of a critical perinatal window, lesions do not form. Mature mice do not develop
cavernomas upon endothelial deletion of CCM genes, despite an increase in KLF4 in the
brain vasculature, so we realized that there must be additional factors that contribute to the
susceptibility of forming lesions. What was the missing ingredient in the adult brain
endothelium? The answer lay in a serendipitous observation upon autopsy of CCM
endothelial knock out animals, revealing numerous blood-filled testicular lesions in the
male mice. In hindsight, it becomes obvious that the reason for the critical neonatal window
of lesion formation was due to the angiogenic milieu of the growing animal. After the
vasculature stopped proliferating when the mouse aged, lesions no longer formed.
Although this explained why mature mice did not develop lesions, it failed to explain why
human patients who also do not have a proliferative brain vasculature in adulthood, can
develop CCM lesions throughout their lifetime.
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The next major clue came from the robust literature surrounding venous and
lymphatic malformations. These diseases are known to be caused by activating mutations
in the PIK3CA gene. As a result, we introduced a gain-of-function PIK3CA allele
containing the H1047R mutation commonly found in cancer into our mouse model. We
observed profound synergy between loss of CCM and gain of PI3K signaling both in the
neonate, and in our newly developed adult model. The present study demonstrates that
either CCM loss of function or PIK3CA gain of function alone are sufficient to confer a
vascular phenotype that is less aggressive in the neonate. Most importantly in the adult
model, neither PIK3CA GOF alone or CCM LOF alone are sufficient to create a lesion. To
our knowledge, this is the first instance of creating CCM lesions in an adult mouse in an
acute setting.
None of these mouse findings are independently groundbreaking without a human
disease correlate. Given the strong synergy in mice, we searched for mutations in resected
human CCM lesions. We identified a significant number of lesions with activating PIK3CA
mutations. In fact, almost 70% of the lesions had one PIK3CA mutations. We likely see
such a high percentage of mutations due to a selection bias of resecting the most aggressive
lesions. We find that both sporadic and familial CCM lesions contain PIK3CA mutations,
suggesting a common mechanism between the two forms of the disease. The rapid growth
of CCM lesions after both CCM loss of function and PIK3CA gain of function are present
in brain endothelial cells in mice, and the finding that mutant cells in human CCM lesions
have triple hits, supports a pathogenesis in which the emergence of a compound mutant
endothelial cell enables a clonal expansion that fuels lesion growth.
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The most translatable conclusion from this work is the identification of an easily
targetable pathway that is already of great pharmaceutical interest. Rapamycin is both
effective on the standard neonatal model by inhibiting basal levels of mTOR and effective
on the new adult model through inhibition of the active PIK3CA. Rapamycin and other
PI3K/AKT/mTOR pathway inhibitors are potential therapeutic agents that will directly
target the cause of lesion growth. The preventative effects of rapamycin are striking,
reducing lesion burden to close to nothing. This opens another avenue of therapeutic
interventions especially for lesions that are difficult to manage surgically.
4.2 Reframing our understanding of vascular malformations
Clinicians and scientists have never been able to explain why a single cavernoma
can suddenly become symptomatic and exhibit rapid growth while having seemingly
equivalent environmental factors that drive all the lesions such as inflammation or the
microbiome. The secret turns out to be in the lesion itself.
To our knowledge, this work describes the first instance of a vascular malformation
shown to be caused by multiple genetic hits in a model analogous to cancer. It has been
described that CCM disease requires biallelic loss of the CCM genes, functioning akin to
the loss of a tumor suppressor genes à la Knudson’s two-hit hypothesis. This was the
prevailing hypothesis for the past decade as the sole driver of CCM formation. However,
it was surprising to all of us to find a third mutation, the additional activating mutation in
PIK3CA which provides the fuel that greatly accelerates growth of the malformation, much
like an oncogenic mutation does in cancer. The implication of this finding is that vascular
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diseases that were previously thought to be caused by a single genetic change could in fact
also have additional mutations that also contribute to its pathogenesis.
When considering simple probability, the chance of acquiring three pathogenic
mutations in three separate alleles within a single cell to form a sporadic CCM seems
infinitesimally small. However - consider the synergy leading to a robust growth
advantage, and it becomes more apparent why even rare events could selectively lead to a
malformation due to the resulting rapid clonal proliferation. As we’ve recently learned
from other published papers, a single activating mutation in MAP3K3 can also synergize
with PIK3CA to form cavernomas, requiring only two hits for the phenotype. Whether
distinct synergistic driver gene combinations underlie other vascular malformations is an
important future question that may be addressed by deeper genomic sequencing of human
vascular malformations. There is a need to consider oncogenic mutations in diseases other
than cancer.
With three separate mutations being identified in the same cell, another question
raised is whether chronology matters in this multiple-hit process or if one mutation
potentially predisposes to acquisition of additional mutations. Given that sporadic CCMs
are often found associated with developmental venous anomalies or DVAs, this work raises
the possibility of DVAs being caused by somatic PIK3CA mutations. Familial CCMs are
unlikely to be associated with DVAs. Alone, the PIK3CA mutation could be the source of
the nascent DVA and remain benign until acquiring two additional hits through loss of
function mutations in CCM genes. This hypothesis is difficult to test due to the lack of
genetic information about DVAs, which are not resected due to the benign nature of the
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anomaly. DVA is found in many individuals with Cowden syndrome, an inherited disease
caused by germline heterozygous loss of function mutations in PTEN that also result in a
gain of PI3K function122,123. An explanation for these clinical observations is that
endothelial cells with pre-existing PIK3CA mutations sufficient to confer DVA
subsequently acquire CCM loss of function mutations and transform into more aggressive
sporadic CCM lesions. While such a clinical pathogenesis remains entirely speculative
until DVA genetic sequencing is performed, it would support a mechanism highly
analogous to cancer in which accrued mutations convert a benign vascular abnormality into
a more malignant one. The Marchuk and Awad lab are working on isolating regions of
human CCM lesions in patients also with DVAs, and sequencing lesional tissue associated
with a DVA or the regions just adjacent to the lesion and looking for a mutation exclusive
to one area.
4.3 Application of a new adult mouse model of CCM disease
The neonatal mouse model of CCM disease has been the gold-standard for field –
the foundational model for all major molecular advances including the role of angiogenesis,
inflammation, the microbiome, and other signaling pathways. Despite the many advantages
to this animal model, as described above, it is not wholly representative of human CCM
disease. CCM disease in humans present throughout the course of a patient’s lifetime, often
well into adulthood, in both familial and sporadic cases. This has confounded the field for
a long time.
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In this work, we generate a new adult CCM mouse model using exogenous delivery
of an AAV-Cre vector through a cranial window, bypassing the brain endothelial cre leak.
In this adult model, neither PI3K GOF nor CCM LOF alone are sufficient, but together,
lead to rapid growth of a cavernoma lesion. The cavernous malformation that forms
resembles a classic mulberry-like vascular lesion, complete with loculations and caverns.
This new model system not only most closely mirrors the molecular pathogenesis that
drives a significant proportion of human CCM lesions containing PIK3CA mutations but
also adds another dimension via the cranial window and targeted micro-injection. This
window permits sequential observation of the brain vasculature and lesions form in a short
time frame that permits analysis of many animals and a direct comparison of different
therapeutics.
The window itself is ultimately a two-dimensional representation of a threedimensional disease process and thus further characterization and refinement of this model
would be beneficial. CCM lesion growth and change in an adult CCM mouse model can
be reliably quantified and monitored in real-time through a cranial window. Local CCM
lesions can be created by direct injection into adult mice and therefore placed in the region
of interest. Visualizing the injected region through the glass coverslip allows monitoring
of lesion formation and growth over time. In addition, this model can be used to observe
flow through the lesion via intravenous injection of fluorescent dextran molecules. In
theory, calculations of cavern flow rate as well as individual cavern number, size, and
growth can be determined. The estimated CCM volume derived from cranial window live

113

imaging can be compared with true volume assessed using microCT imaging. Correlation
with microCT could also measure extralesional hemorrhage.
There are a couple concerns regarding this model. First, the virus is injected directly
into the parenchyma of the brain and therefore cannot ensure specific endothelial targeting
of the virus. However, the endothelial requirement for the molecular pathway has already
been shown in multiple animal models. Though the imprecise nature of this system is a
flaw of this model, we believe this to still be the best animal CCM model to date. Secondly,
PI3K signaling is artificially elevated in this model, making it difficult to study the effects
of the CCM pathway alone. This is perhaps most equivalent to aggressive human disease
and therefore is valuable as a disease model even outside the scope of pure mechanistic
studies.
4.4 Evaluating CCM therapeutics and lesion regression
With the development of a new adult mouse model through this neurosurgical
technique, we open many doors for translational developments. There are a couple clear
avenues to pursue utilizing the adult mouse model that I will delve into below:
1) Pre-clinical model of pharmacologic agents for the treatment of CCM
In the past two decades, a large number of pharmacologic therapies have been
proposed alongside the advances in our understanding of the CCM signaling pathway.
These drugs include statins, beta blockers, and ROCK inhibitors, to complement an already
robust neurosurgical approach. Most of these drugs have gone directly from zebrafish or
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neonatal mouse studies to human clinical trials, despite lacking a reliable means of
preclinical testing42,181,182.
Many of the drugs that have proven effective in the neonatal mouse model are not
suitable agents for long term use in a growing animal. For example, experiments using
rapamycin as discussed earlier were very effective in reducing lesion burden in the neonate,
but these animals also had severely retarded growth, and were not able to tolerate even the
single dose of rapamycin for an extended duration. In contrast, the adult AAV animals
treated with rapamycin tolerated the drug treatment much better with no change in weight
over the course of daily treatment. CCM growth can be quantitated both visually through
the cranial window and by microCT in a blinded manner. As a result, the new adult model
serves as a reliable and reproducible preclinical model for quantitative assessment of
putative CCM therapies.
Initially, there are a couple easy candidates for testing in this model as a direct
extension of the work detailed above. Namely, the drugs that are already under multi-center
randomized clinical trials such as atorvastatin and Fasudil181,183. Also, proposed treatments
such as rapamycin and propranolol42,184,185 could be promising avenues. We can administer
these agents to mice before inducing CCM lesions and compare the growth across different
treatments. We can quantify lesion changes including regression, progression and
stabilization with serial real-time microscopic imaging and microCT quantification.
2) CCM lesion regression
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Perhaps most importantly, this new adult mouse model allows us to test a key
clinical question that has never previously been able to be answered – whether CCM
treatment can only prevent new lesion or growth, or whether it might also be able to drive
lesion regression and thereby provide a true medical alternative to neurosurgical resection.
With the neonatal mouse model, it is impossible to visualize the growth of an individual
lesion. This is because (1) all quantitative metrics are obtained after euthanasia of the
animal and harvesting the brain for microCT quantitation and (2) the model creates
multiple lesions that occur throughout the hindbrain and would be difficult to track besides
relying on bulk volume. As a result, any attempt at using lesion burden at defined
euthanasia endpoints would require an enormous number of animals to determine whether
lesion burden, averaged over many animals could potentially decrease. Ultimately, this
study is a poor substitute for the ability to track a single lesion over time and the resources
required made it a difficult study to pursue up until this point.
Our new adult model requires both CCM loss of function and PIK3CA gain of
function for CCM growth, and growth in this model can be blocked by the mTORC1
antagonist Rapamycin. Alone, neither is sufficient for lesion growth. With pharmacologic
inhibition at post-op day 7 prior to formation of the lesion, we can also substantially prevent
any growth. Unlike the experiments performed in the paper, we have not tested whether
removal of one of these inputs after a lesion has already formed would result in lesion
regression. The hypothesis we propose is that CCM lesions can regress if these signaling
abnormalities are genetically or pharmacologically corrected. To test this hypothesis, I can

116

use the adult model to test whether genetic reversal of PIK3CA signaling or Rapamycin
treatment can lead to regression of already formed CCM lesions.
An experiment that is under works is using a genetic system that will allow control
over this synergy, through use of a tetracycline-inducible which I refer to as tetO-PIK3CA.
In the genetic model, I will use a tetracycline-inducible mutant PIK3CA transgene along
with floxed CCM genes to create CCM lesions in adult mice and then genetically turn off
the PIK3CA gain of function. This experiment is very similar to the original experiment
completed in the paper as described in Chapter 2, but requires an additional step due to the
tetracycline tetO promoter which activates transcription of the target gene, in this case the
mutant Pik3ca H1047R. Combining this with a cre-driven tTA system, we will have
temporal control over activation of the gene as well as inhibition of the gene. This tet-Off
system means that tetracycline/doxycycline will prevent the tetracycline transactivator
protein from binding and therefore turns the gene off, thus removing the mutant PIK3CA
signal.
An important caveat – doxycycline is a mild antibiotic, and it will result in
microbiome changes. As previous work in our lab has shown, loss or change in the
composition of gut bacteria dramatically effects the phenotype in the neonatal CCM model.
We still do not know how or if antibiotics/microbiome changes our adult phenotype. It is
very possible that the gut microbiome in the mature animal no longer plays as large of a
role especially compared with aberrant PI3K signaling. This will also be an important and
interesting thing to test down the line.
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Pharmacologically, we can perform the equivalent experiment with Rapamycin and
other drugs in mice with already formed CCM lesions. Significantly, the genetic and
pharmacologic approaches are complementary and both important avenues to pursue. The
genetic approach is absolute and negative results unlikely to be due to incomplete blockade;
the pharmacologic approach is a more realistic pre-clinical model.
4.5 Remaining questions
Though we have solved some mysteries surrounding CCM, as any good scientific
study does, we have also raised further questions about our findings. There are many
remaining questions left to answer that these observations and experiments do not
completely address.
(1) What is unique about PIK3CA? Not a single other pathogenic mutation was picked up
by the sequencing panel (see methods chapter for comprehensive list) including mutations
in the components of or modulators of the PI3K pathway such as AKT1, MTOR, TSC1/2,
or PTEN. Even outside of the PI3K pathway, canonical oncogenes such as KRAS, RAF,
and TP53 were not found to have any activating mutations. Preliminary experiments using
a KRAS mutant gain-of-function allele (data not shown) also showed synergy with loss of
CCM in the mouse. Notably, unlike PIK3CA GOF, there was no overt gross phenotype
with KRAS GOF alone. What explains the predilection for PIK3CA mutations in CCM
lesions? It is possible that PIK3CA sits in the “sweet spot” of the pathway and other
mutations further upstream or downstream would be insufficient to provide the same
amount of synergy.
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(2) What is the exact mechanism of synergy? We have identified PI3K as downstream of
KLF2/4 signaling, though it does not explain the full extent of the synergy observed. We
do not know which target genes of KLF2/4 are responsible for the gain of PI3K signaling,
despite evaluating bioinformatic databases for clues. As described above, the phenotype of
PI3K GOF neonate alone is similar to, but not the same as CCM loss, indicating other
important downstream pathways of CCM loss. There are multiple avenues of crosstalk yet
to be examined – including the role of upstream angiogenic factors like VEGF/VEGFR2
signaling, as well as other growth-related kinase cascades such as MAPK/ERK signaling
which also converges at phospho-S6. Testing other pathways will be an important step in
identifying the point of synergy and better understand the molecular relationship between
the CCM complex and PI3K.
(3) What is the role of cell-nonautonomous mechanisms in lesion growth? Multiple papers
have described incorporation of wild-type cells into the growing lesion92,186. Our lab has
also shown that extracellular cleavage of versican by ADAMTS5 proteases play an
important role in the formation of a lesion and that loss of these proteases can rescue the
severity of the phenotype47. How do we reconcile the seemingly opposing observations of
PI3K acting in a cell-autonomous fashion to spur lesion growth with the observation that
lesions are composed of mostly wild-type endothelium? Does PI3K-stimulated clonal
expansion drive most of the lesion growth and bring wild-type cells along for the ride, or
do wild-type cells play an active role in forming a lesion?
(4) Why the predisposition for the central nervous system? Familial patients are germline
heterozygous for loss of function mutations in one of the CCM genes in all the cells
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throughout their body. One could reasonably anticipate these lesions forming anywhere on
body assuming a similar frequency of mutations yet lesions still tend to form in the
vasculature of the CNS. Even in the neonatal mouse model, global endothelial deletion
only results in CCM lesions that form in the brain and retina. The reason for this tissuespecific localization of the lesion is still a mystery, though one could anticipate a CNSspecific environmental factor that contributes to lesion formation.
(5) Finally, what does this mean for the clinical treatment of CCMs? These discoveries,
albeit promising therapeutically, do not prove to be immediately worthwhile and the
clinical indication for potential use of rapamycin is yet to be seen. Most CCMs remain
benign and do not need to be treated. We do not know if rapamycin will stabilize a lesion,
minimize neurologic symptoms, or prevent hemorrhage. As with any treatment, the side
effect profile of rapamycin could make it unsuitable for long term use in patients.
Ultimately the only definitive answer will be after bringing these drugs to clinical trial.
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